var title_f10_52_11072="Slit lamp chin rest";
var content_f10_52_11072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp chin rest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adjust the chin rest height so that the pupils are aligned with the marker.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11072=[""].join("\n");
var outline_f10_52_11072=null;
var title_f10_52_11073="Lormetazepam: International drug information";
var content_f10_52_11073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lormetazepam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldosomnil (ES);",
"     </li>",
"     <li>",
"      Dilamet (AR);",
"     </li>",
"     <li>",
"      Ergocalm (DE);",
"     </li>",
"     <li>",
"      Loramet (BE, CH, ES, GR, HK, NL, SG, TH, ZA);",
"     </li>",
"     <li>",
"      Loretam (DE);",
"     </li>",
"     <li>",
"      Minias (IT);",
"     </li>",
"     <li>",
"      Noctamid (AT, BE, CH, DE, ES, IE, NL, NZ, PT, ZA);",
"     </li>",
"     <li>",
"      Noctamide (FR);",
"     </li>",
"     <li>",
"      Nocton (CL);",
"     </li>",
"     <li>",
"      Octonox (BE);",
"     </li>",
"     <li>",
"      Pronoctan (DK);",
"     </li>",
"     <li>",
"      Sedaben (BE);",
"     </li>",
"     <li>",
"      Stilaze (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2638246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2638247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2638249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usual dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 0.5-1.5 mg once daily prior to bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elderly: 0.5 mg once daily prior to bedtime; maximum dose: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2638250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Capsule: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10471 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11073=[""].join("\n");
var outline_f10_52_11073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369843\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638246\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638247\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638249\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821115\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638250\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_52_11074="MRI subdural hematoma";
var content_f10_52_11074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of the brain demonstrates a spontaneous subdural hematoma over the right cerebral hemisphere",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11074=[""].join("\n");
var outline_f10_52_11074=null;
var title_f10_52_11075="Cross-reactivity of topical corticosteroids";
var content_f10_52_11075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Coopman classification of cross-reactivity in allergic reactions to topical corticosteroids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 779px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Torres MJ, Canto G. Hypersensitivity reactions to corticosteroids. Curr Opin Allergy Clin Immunol 2010; 10:273. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11075=[""].join("\n");
var outline_f10_52_11075=null;
var title_f10_52_11076="Abciximab: Patient drug information";
var content_f10_52_11076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Abciximab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     see \"Abciximab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reopro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F128992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ReoPro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during a heart treatment to protect the arteries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of heart attacks in patients who have unstable angina or mild heart attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to abciximab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to mouse proteins, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Aneurysm, arteriovenous malformations, bleeding problems, brain tumor, low platelet count, recent surgery or injury, stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10897 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11076=[""].join("\n");
var outline_f10_52_11076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128991\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128992\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017222\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017224\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017223\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017228\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017229\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017231\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017226\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017227\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017232\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017233\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=related_link\">",
"      Abciximab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_52_11077="Omental cake ovarian CA";
var content_f10_52_11077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian cancer metastatic to the omentum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large omental cake (C) overlying small bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Mann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11077=[""].join("\n");
var outline_f10_52_11077=null;
var title_f10_52_11078="Vandetanib: Patient drug information";
var content_f10_52_11078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vandetanib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     see \"Vandetanib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13034485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Caprelsa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13812981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Caprelsa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12760624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An unsafe fast heartbeat may happen. Tell your doctor if you have a history of fast heartbeats, low potassium or magnesium levels. Your heartbeat will be watched with an ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get this drug only from the Vandetanib REMS Program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12760646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat thyroid cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12760606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vandetanib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a long QT on ECG.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12760608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low potassium or magnesium level, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12760963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A faster, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12760610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin on hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12760647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may put tablet in",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       cup of water, mix for 10 minutes and drink. Rinse cup with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup more water and drink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12760607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is less than 12 hours until the next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12760966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12760611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16485 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11078=[""].join("\n");
var outline_f10_52_11078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13034485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13812981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760624\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760646\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760606\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760608\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760963\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760610\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760647\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760607\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760966\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12760611\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=related_link\">",
"      Vandetanib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_52_11079="Pediculosis corporis louse";
var content_f10_52_11079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80539%7EDERM%2F86443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80539%7EDERM%2F86443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculus humanus humanus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Human body louse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koneman's Color Atlas and Textbook of Diagnostic Microbiology, Fifth Edition, Lippincott-Raven, Philadelphia 1997. Copyright &copy; 1997 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pediculosis humanus humanus (human body louse)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo provided by B. Thomas Photo Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11079=[""].join("\n");
var outline_f10_52_11079=null;
var title_f10_52_11080="Benzodiazepine poisoning and withdrawal";
var content_f10_52_11080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Benzodiazepine poisoning and withdrawal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Howard Greller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Amit Gupta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11080/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/52/11080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines (BZD) are sedative-hypnotic agents that have been in clinical use since the 1960s. The first benzodiazepine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    , was discovered serendipitously in 1954 by the Austrian scientist Leo Sternbach. Three years later, it was marketed as a therapeutic medication under the brand name Librium. Following chlordiazepoxide in 1963,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    was released followed by multiple other compounds over subsequent years.",
"   </p>",
"   <p>",
"    BZDs are used for sedation and to treat anxiety, seizures, withdrawal states, insomnia, and drug-associated agitation. They are frequently combined with other medications for procedural sedation. Due to their many uses, BZDs are widely prescribed and nearly 50 different agents are available worldwide. The high incidence of BZD overdose mirrors their widespread use and availability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of acute benzodiazepine poisoning will be reviewed here. A general approach to the poisoned patient and the management of poisonings involving other agents with sedative properties are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link\">",
"     \"Ethanol intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines (BZD) are organic bases with a benzene ring and a seven member diazepine moiety; various side chains determine the potency, duration of action, metabolite activity, and rate of elimination for specific agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/3\">",
"     3",
"    </a>",
"    ]. BZDs exert their effect via modulation of the gamma-aminobutyric acid A (GABA-A) receptor. Gamma-aminobutyric acid (GABA) is the chief inhibitory neurotransmitter of the central nervous system.",
"   </p>",
"   <p>",
"    The GABA-A receptor is composed of five subunits (alpha, beta, and gamma) arranged in various combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. The composition of subunits determines the affinity of the various xenobiotics that bind to the receptor. Benzodiazepines bind at the interface of the alpha and gamma subunits and, once bound, lock the GABA-A receptor into a conformation that increases its affinity for GABA. BZDs do not alter the synthesis, release, or metabolism of GABA but rather potentiate its inhibitory actions by augmenting receptor binding. This binding increases the flow of chloride ions through the GABA ion channel, causing postsynaptic hyperpolarization and a decreased ability to initiate an action potential. The low incidence of respiratory depression with orally ingested BZDs appears to be related to the low density of binding sites in the brainstem respiratory center [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are commonly divided into three groups based upon half-life duration: short-acting (half-life of less than 12 hours), intermediate-acting (half-life between 12 and 24 hours), and long-acting (half-life greater than 24 hours). A table describing the kinetics of common BZDs is provided (",
"    <a class=\"graphic graphic_table graphicRef69184 \" href=\"UTD.htm?36/19/37181\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Short-acting benzodiazepines generally have few active metabolites, do not accumulate with repeated doses, and demonstrate clearance that is largely unaffected by age and liver disease. Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"     triazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    . Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    possesses a short half-life, it has active metabolites that can accumulate with repeated dosing.",
"   </p>",
"   <p>",
"    Intermediate-acting benzodiazepines include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    . Long-acting benzodiazepines generally have pharmacologically active metabolites, accumulate in tissues after multiple doses, and demonstrate impaired clearance in older patients and those with liver disease. Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BZDs are rapidly absorbed in the GI tract and most are highly lipophilic and highly protein bound. The metabolism of BZDs is primarily hepatic. Within the liver, most BZDs are metabolized to a significant extent by the CYP2C19 and CYP3A4 enzymes.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     Alprazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    are metabolized by CYP3A4.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    is metabolized by both CYP3A4 and CYP2C19.",
"   </p>",
"   <p>",
"    Interactions with other drugs that are metabolized by CYP enzymes may prolong the half-lives of certain BZDs, leading to prolonged clinical effects and therapeutic misadventures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Examples of drugs that inhibit the CYP3A4 enzyme and reduce the metabolism of BZDs thereby prolonging their effects, include macrolide antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , HIV protease inhibitors, and grapefruit juice (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 2",
"    </a>",
"    ). Inducers of CYP3A4, which may enhance metabolism of BZDs, include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and St. John's wort (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     Oxazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are directly conjugated to an inactive, water-soluble glucuronide metabolite that is excreted by the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Therefore, these agents are not susceptible to CYP interactions and are less likely to accumulate in patients with CYP inhibition.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     Chlordiazepoxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=see_link\">",
"     flurazepam",
"    </a>",
"    are metabolized to active metabolites, which then are conjugated and excreted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main active metabolite of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    is desmethyldiazepam. Diazepam's other active metabolites include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    . Active metabolites of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    include desmethylchlordiazepoxide, demoxepam, desmethyldiazepam, and oxazepam.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"     Triazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    are converted to hydroxylated intermediates that are rapidly conjugated and do not contribute to the drug's overall effect.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    has a very rapid onset of clinical effect and a shorter duration of action than other benzodiazepines, which explains its preferential use in procedural sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/14\">",
"     14",
"    </a>",
"    ]. However, successive doses of midazolam lead to bioaccumulation of its hydroxy-metabolites and may prolong the drug's sedative effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Benzodiazepine poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral benzodiazepines (BZD) taken in overdose without a coingestant rarely cause significant toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/16\">",
"     16",
"    </a>",
"    ]. The classic presentation of a patient with an isolated BZD overdose consists of CNS depression with normal vital signs. Many patients are arousable and able to provide an adequate history. Of note, most intentional ingestions of BZDs involve a coingestant, the most common being ethanol.",
"   </p>",
"   <p>",
"    Patients with a clinically apparent ingestion manifest slurred speech, ataxia, and altered (most commonly depressed) mental status. Respiratory compromise is uncommon with isolated oral ingestions, but may be seen when patients ingest additional sedative hypnotic agents (such as ethanol) or when clinicians administer BZDs as one of several agents for procedural sedation. The latter scenario more often leads to respiratory depression due to the intravenous administration of BZDs and the consequent rapid rise in central nervous system concentrations.",
"   </p>",
"   <p>",
"    The doses required to produce respiratory compromise are difficult to quantify and depend upon many factors, including tolerance, weight, age, coingestants, and genetics.",
"   </p>",
"   <p>",
"    Patients with severe toxicity can present stuporous or comatose. One observational study found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    to be the least and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    the most sedating BZD in intentional overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/17\">",
"     17",
"    </a>",
"    ]. The authors speculate that this is because temazepam is more rapidly absorbed and oxazepam more slowly absorbed than other BZDs. Another observational study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    overdose resulted in significantly longer hospital stays, higher ICU admission rates, and a greater need for mechanical ventilation and the use of reversal agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/18\">",
"     18",
"    </a>",
"    ]. These studies, while providing some information, are limited by their observational nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Propylene glycol poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propylene glycol (1,2 propanediol) is the diluent used in parenteral formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and the cause of a unique complication related to the prolonged parenteral administration of these BZDs. The potential effects of PG toxicity include skin and soft tissue necrosis (from extravasation), hemolysis, cardiac dysrhythmias, hypotension, lactic acidosis, seizure, coma, and multisystem organ failure.",
"   </p>",
"   <p>",
"    PG toxicity is rare but may be considered when patients receiving large or continuous infusions of parenteral BZDs (eg, mechanical ventilation, severe sedative hypnotic or ethanol withdrawal syndromes, undifferentiated agitated delirium, management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    overdose) develop an anion gap metabolic acidosis. The osmolal gap correlates with PG concentrations and can be used as a surrogate marker of PG toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/19\">",
"     19",
"    </a>",
"    ]. PG poisoning from IV BZD infusions is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link&amp;anchor=H8#H8\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\", section on 'Propylene glycol toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, PG is also used in food, cosmetics, and oral medicines, and rare cases of poisoning from intentional ingestion have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered mental status, a common finding in BZD overdose, is found in a wide range of medical and toxicologic conditions (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=see_link\">",
"     \"Evaluation of abnormal behavior in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BZD overdose is usually suspected on the basis of history and the clinical scenario. Any number of sedative-hypnotic medications share clinical features with BZDs in overdose, including ethanol, barbiturates, gamma hydroxybutyrate (GHB), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sedative hypnotic toxidrome is characterized by a depressed mental status, an unremarkable physical examination, and normal vital signs, hence the common description \"coma with normal vitals.\" Ethanol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    intoxication can be ruled out by obtaining serum concentrations. Patients with gamma hydroxybutyrate intoxication often manifest abrupt alterations in mental status without intervention and severe respiratory depression can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link\">",
"     \"Ethanol intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=see_link\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other life-threatening causes of depressed mental status must be considered in the differential diagnosis, including hypoglycemia and carbon monoxide exposure. Stroke, meningitis and encephalitis, and head trauma can present with altered mental status and should be investigated as clinically indicated. An isolated overdose with oral BZDs rarely causes profound respiratory depression requiring invasive airway management or cardiopulmonary instability. In such cases, the presence of coingestants should be investigated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link\">",
"     \"Viral encephalitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Testing for benzodiazepine toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines (BZDs) are themselves NOT detected in standard urine screening tests for drugs of abuse. However, the most common BZD urine test identifies metabolites of 1,4-benzodiazepines, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    . This test may not detect",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A number of factors, such as the amount of drug ingested, the presence of coingestants, and patient age and weight, can alter pharmacokinetics and affect urine drug tests. In general, BZD metabolites can be detected as early as three hours after ingestion and may remain detectable for up to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum BZD concentrations are not routinely available in the emergency setting, correlate poorly with clinical findings, and do not aid management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of the poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is reasonable to obtain a serum ethanol concentration in patients with suspected BZD overdose, given the difficulty of distinguishing between the clinical effects of BZDs and ethanol.",
"   </p>",
"   <p>",
"    Clinicians should obtain additional tests based upon clinical findings. As examples, altered mental status in association with fever raises concern for meningitis or other infections and warrants a thorough evaluation, including assessment of the cerebral spinal fluid. A head computed tomography scan should be obtained if there is external evidence or concern for head trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any poisoning, the management of benzodiazepine (BZD) overdose begins with a rapid assessment of the patient's airway, breathing, and circulation. Endotracheal intubation should not be delayed if needed. Oxygen is administered, intravenous access established, and continuous cardiac monitoring employed. A fingerstick serum glucose is immediately obtained. End tidal CO2 (ie, capnography) can be useful for monitoring patients at risk for hypoventilation, as can occur with severe benzodiazepine overdose. General discussions of the basic facets of the management of poisonings are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of isolated BZD overdose, a history, physical examination (with particular attention paid to signs of respiratory dysfunction, trauma, and poisoning from coingestants), and regular monitoring are likely to be all that is necessary. The period of observation and disposition depend upon clinical findings. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal decontamination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) is usually of NO benefit in cases of isolated BZD ingestion and increases the risk of aspiration. We suggest that patients with BZD overdose NOT be treated with AC, unless a life-threatening coingestant amenable to treatment with charcoal is suspected and the patient&rsquo;s airway is protected (naturally or with a tracheal tube).",
"   </p>",
"   <p>",
"    Whole bowel irrigation is generally unnecessary because of the rarity of sustained release preparations and the difficulty of initiating treatment in the obtunded patient. Neither multidose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    nor hemodialysis is effective as an enhanced elimination technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antidote (flumazenil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     Flumazenil",
"    </a>",
"    is a nonspecific competitive antagonist of the BZD receptor. It can be used to reverse BZD-induced sedation following general anesthesia, procedural sedation, or overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, the use of flumazenil in the setting of overdose remains highly controversial. Administration of flumazenil can precipitate withdrawal seizures in patients who have developed a tolerance to BZDs through chronic use or abuse. Such risks may be further increased if the patient has taken coingestants with proconvulsant properties [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Of note, flumazenil does NOT consistently reverse respiratory depression caused by BZD overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because oral BZD overdose has a low rate of morbidity and mortality is rare, the risks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    treatment often outweigh its benefits. The purported benefit of flumazenil is to avoid the need for procedures, such as endotracheal intubation, CT imaging, and lumbar puncture, should the patient's mental status return to normal when the BZD's sedative effects are reversed. We suggest consultation with a medical toxicologist or poison control center whenever the use of flumazenil is contemplated. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     Flumazenil",
"    </a>",
"    appears to be safe and effective when used to reverse the sedating effects of a BZD given for procedural sedation in patients who do not use BZDs chronically. In adults, the recommended initial dose is 0.2 mg given intravenously (IV) over 30 seconds. Repeated doses of 0.2 mg, to a maximum dose of 1 mg, can be given until the desired effect is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/24\">",
"     24",
"    </a>",
"    ]. In the event of resedation, the dosing regimen described here can be repeated, but no more than 3 mg of flumazenil should be given within any one hour.",
"   </p>",
"   <p>",
"    In children, the initial dose is 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given IV over 15 seconds (maximum dose 0.2 mg). The initial dose may be followed at one or more minute intervals with up to four repeat doses of 0.005 to 0.01",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 0.2 mg) per dose. The maximum dose should NOT exceed 1 mg total or 0.05",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    the lower dose is preferable.",
"   </p>",
"   <p>",
"    The peak effect of a single",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    dose occurs approximately 6 to 10 minutes after IV administration. For patients at greater risk of seizure or agitation with BZD reversal, a longer wait of several minutes between subsequent doses may be warranted.",
"   </p>",
"   <p>",
"    The duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    is short (0.7 to 1.3 hours) and the duration of effect of a long-acting BZD or a large BZD dose can exceed that of flumazenil. Resedation may be treated in adults by using 0.2 mg doses (maximum total dose 1 mg) until the desired effect is achieved. For patients with exposures to BZDs with prolonged durations of action or those with hepatic insufficiency with prolonged exposure to BZDs, a continuous flumazenil infusion (0.25 to 1 mg per hour) may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Again, we suggest consultation with a medical toxicologist or poison control center whenever a flumazenil infusion is thought to be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who require mechanical ventilation or have been exposed to a dangerous coingestant are admitted to a critical care setting.",
"   </p>",
"   <p>",
"    Most patients with an isolated BZD ingestion can be safely discharged or transferred for psychiatric evaluation following an observation period of four to six hours, provided that any concerning symptoms, such as CNS depression, have resolved. The patient should be able to ambulate safely by the end of this period. Patients with persistent signs of intoxication beyond six hours should be admitted to a monitored setting until symptoms resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     WITHDRAWAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mechanism, signs, and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any abrupt or overly rapid reduction in benzodiazepine (BZD) dose among chronic users can produce withdrawal. Rapid recognition and treatment of BZD withdrawal is crucial because the syndrome can be life-threatening. The symptoms and signs of BZD withdrawal can include tremors, anxiety, perceptual disturbances, dysphoria, psychosis, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of withdrawal varies according to the half-life of the BZD involved. Symptoms may be delayed up to three weeks in BZDs with long half-lives, but may appear as early as 24 to 48 hours after cessation of BZDs with short half-lives. The severity and duration of withdrawal is determined by many factors, including the period of BZD use, how rapidly use was tapered (if at all), and possibly patient genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic ingestion of BZDs leads to conformational changes in the GABA receptor, which ultimately reduce the receptor's affinity for the agent and result in decreased GABA activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/27\">",
"     27",
"    </a>",
"    ]. This decreased activity manifests as tolerance to the agent. When BZDs are no longer present or present at lower concentrations, this decreased GABA receptor activity has less inhibition of excitatory neurotransmitters, and thus, there is a pro-excitatory state.",
"   </p>",
"   <p>",
"    Withdrawal can usually be avoided or minimized through the use of BZDs with a long half-life, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    , and a gradual tapering of the patient's BZD dose over several months, depending upon the dosage and degree of dependency. Tapering strategies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;BZD withdrawal is treated with a BZD that has a prolonged clinical effect, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , given intravenously and titrated to effect. The goal is to eliminate withdrawal symptoms without causing excessive sedation or respiratory depression. Once symptoms are controlled, the BZD dose should then be tapered gradually over a period of months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Tapering strategies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients in mild BZD withdrawal, a long-acting oral BZD may be given; it is also reasonable to give such a patient the BZD that they had been using chronically.",
"   </p>",
"   <p>",
"    A number of medications have been used to treat BZD withdrawal, but none has been found to be as effective as BZDs. Beta blockers, antipsychotics, selective serotonin reuptake inhibitors, and antihistamines have all been shown to be inferior to standard treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Although no controlled trials have assessed valproic acid in the treatment of BZD withdrawal, a systematic review of valproic acid for the management of alcohol withdrawal found no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/32\">",
"     32",
"    </a>",
"    ]. Another systematic review identified one trial in which carbamazepine showed a trend toward benefit in BZD withdrawal, but this was in patients already receiving BZD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11080/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Pending further study, treatments other than BZDs cannot be recommended for the management of BZD withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzodiazepines (BZD) are widely prescribed and commonly involved in cases of drug overdose and substance abuse. They are commonly categorized by half-life duration (",
"      <a class=\"graphic graphic_table graphicRef69184 \" href=\"UTD.htm?36/19/37181\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral BZDs taken in overdose without a coingestant rarely cause significant toxicity. The classic presentation of a patient with an isolated BZD overdose consists of CNS depression with normal vital signs. Severe overdose can cause respiratory depression and stupor or coma. Coingestants are common in cases of overdose. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Propylene glycol (1,2 propanediol), the diluent used in parenteral formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      , is the cause of a unique and rare complication related to prolonged parenteral administration of BZDs. Potential adverse effects include hemolysis, cardiac dysrhythmias, hypotension, lactic acidosis, seizure, coma, and multisystem organ failure.",
"     </li>",
"     <li>",
"      Altered mental status, a common finding in BZD overdose, is found in a wide range of medical and toxicologic conditions (",
"      <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"       table 4",
"      </a>",
"      ). Life-threatening causes of depressed mental status include hypoglycemia, carbon monoxide poisoning, stroke, meningitis and encephalitis, and head trauma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BZDs are NOT detected in standard urine screening tests for drugs of abuse. However, the most common BZD urine test identifies metabolites of 1,4-benzodiazepines, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      . This test may not detect",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      . The need for further testing is discussed in the text. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of isolated BZD ingestion are managed successfully with supportive care alone. Gastrointestinal decontamination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) is usually of NO benefit and increases the risk of aspiration. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"       Flumazenil",
"      </a>",
"      is a nonspecific competitive antagonist of the BZD receptor. It can be used to reverse BZD-induced sedation following general anesthesia, procedural sedation, or overdose. Administration of flumazenil can precipitate withdrawal seizures in patients who have developed a tolerance to BZDs. Therefore, the use of flumazenil in the setting of overdose remains highly controversial. We suggest consultation with a medical toxicologist or poison control center whenever the use of flumazenil is contemplated. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antidote (flumazenil)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any abrupt or overly rapid reduction in BZD dose among chronic users can produce withdrawal. Rapid recognition and treatment of BZD withdrawal is crucial because the syndrome can be life-threatening. Symptoms and signs can include tremors, anxiety, perceptual disturbances, dysphoria, psychosis, and seizures. BZD withdrawal is treated with a BZD that has a prolonged clinical effect (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      ) given intravenously and titrated to effect. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Drug Abuse Warning Network: The DAWN Report. April 2004. Benzodiazepine in Drug-Abuse Related Emergency Department Visits: 1995-2002. www.oas.samhsa.gov/2k4benzodiazepinesTrends.pdf (Accessed on May 04, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/2\">",
"      Lader M. Benzodiazepines revisited--will we ever learn? Addiction 2011; 106:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/3\">",
"      Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/4\">",
"      Hevers W, L&uuml;ddens H. The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol 1998; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/5\">",
"      Smith TA. Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Br J Biomed Sci 2001; 58:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/6\">",
"      Ali NJ, Olsen RW. Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms. J Neurochem 2001; 79:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/7\">",
"      Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/8\">",
"      Potokar J, Coupland N, Wilson S, et al. Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. Psychopharmacology (Berl) 1999; 146:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/9\">",
"      Snead OC 3rd, Nichols AC, Liu CC. gamma-Hydroxybutyric acid binding sites: interaction with the GABA-benzodiazepine-picrotoxin receptor complex. Neurochem Res 1992; 17:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/10\">",
"      Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/11\">",
"      Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/12\">",
"      Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol 1981; 11 Suppl 1:11S.",
"     </a>",
"    </li>",
"    <li>",
"     Wynn, G, Oesterheld, J, Cozza, K, Armstong, G. Clinical manual of drug interaction principles for medical practice. Chapters 2, 3, 19. American psychiatric publishing Inc, Washington, DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/14\">",
"      Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997; 15:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/15\">",
"      Bauer TM, Ritz R, Haberth&uuml;r C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/16\">",
"      H&ouml;jer J, Baehrendtz S, Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med 1989; 226:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/17\">",
"      Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. BMJ 1995; 310:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/18\">",
"      Isbister GK, O'Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 2004; 58:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/19\">",
"      Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 2005; 25:8S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/20\">",
"      Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/21\">",
"      Weinbroum AA, Flaishon R, Sorkine P, et al. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf 1997; 17:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/22\">",
"      Seger DL. Flumazenil--treatment or toxin. J Toxicol Clin Toxicol 2004; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/23\">",
"      Shalansky SJ, Naumann TL, Englander FA. Effect of flumazenil on benzodiazepine-induced respiratory depression. Clin Pharm 1993; 12:483.",
"     </a>",
"    </li>",
"    <li>",
"     Romazicon package insert. Roche Pharmaceuticals. www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6844 (Accessed on May 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/25\">",
"      Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. Pharmacotherapy 2003; 23:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/26\">",
"      H&ouml;jer J, Baehrendtz S, Magnusson A, Gustafsson LL. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta Anaesthesiol Scand 1991; 35:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/27\">",
"      Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf 1993; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/28\">",
"      Hood HM, Metten P, Crabbe JC, Buck KJ. Fine mapping of a sedative-hypnotic drug withdrawal locus on mouse chromosome 11. Genes Brain Behav 2006; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/29\">",
"      Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr 2009; 67:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/30\">",
"      Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/31\">",
"      Denis C, Fats&eacute;as M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006; :CD005194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/32\">",
"      Lum E, Gorman SK, Slavik RS. Valproic acid management of acute alcohol withdrawal. Ann Pharmacother 2006; 40:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11080/abstract/33\">",
"      Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991; 48:448.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 314 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11080=[""].join("\n");
var outline_f10_52_11080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Benzodiazepine poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Propylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Testing for benzodiazepine toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antidote (flumazenil)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mechanism, signs, and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/19/37181\" title=\"table 1\">",
"      Benzodiazepine and other hypnotic drug kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 2\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/43/3773\" title=\"table 3\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/11/1214\" title=\"table 4\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34311?source=related_link\">",
"      Evaluation of abnormal behavior in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31130?source=related_link\">",
"      Gamma hydroxybutyrate (GHB) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_52_11081="Overview of benign breast disease";
var content_f10_52_11081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of benign breast disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11081/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11081/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11081/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/52/11081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign breast disease represents a spectrum of disorders that come to clinical attention as imaging abnormalities or as palpable lesions found on physical examination. Following establishment of a benign diagnosis, treatment in general is aimed at symptomatic relief and patient education.",
"   </p>",
"   <p>",
"    Some benign breast diseases, such as atypical hyperplasia, confer an increase in the patient's future risk of developing breast cancer, and should lead to counseling about screening recommendations and risk reduction strategies. These lesions are considered risk markers, rather than premalignant, because those cancers that subsequently develop are not necessarily in the area of the atypia, and may occur in the contralateral breast.",
"   </p>",
"   <p>",
"    This topic will review the pathologic classification and treatment of benign breast disorders. Evaluation of women presenting with symptoms related to the breast and diagnosis of breast disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=see_link\">",
"     \"Breast pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF BENIGN BREAST LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign epithelial breast lesions can be classified histologically into three categories: nonproliferative, proliferative without atypia, and atypical hyperplasia. The categorization is based upon the degree of cellular proliferation and atypia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link\">",
"     \"Breast development and morphology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NONPROLIFERATIVE BREAST LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonproliferative epithelial lesions are generally not associated with an increased risk of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/1\">",
"     1",
"    </a>",
"    ]. It should be noted that terms such as fibrocystic changes, fibrocystic disease, chronic cystic mastitis, and mammary dysplasia refer to nonproliferative lesions and are not useful clinically, as they encompass a heterogeneous group of diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. The most common nonproliferative breast lesions are breast cysts. Other nonproliferative lesions include papillary apocrine change, epithelial-related calcifications and mild hyperplasia of the usual type [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Simple breast cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple cysts are fluid filled, round or ovoid masses derived from the terminal duct lobular unit. Breast cysts can present as breast masses or mammographic abnormalities. Cysts are common in women between 35 and 50 years old. Acute enlargement of cysts may cause severe, localized pain of sudden onset. The diagnosis and management of breast cysts is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link\">",
"     \"Breast cysts: Clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Papillary apocrine change",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary apocrine change is a proliferation of ductal epithelial cells showing apocrine features, characterized by eosinophilic cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epithelial-related calcifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial related calcifications are benign calcifications that are observed in breast tissue and can be seen in normal ducts and lobules, breast stroma or blood vessel walls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mild hyperplasia of the usual type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild hyperplasia of the usual type is an increase in the number of epithelial cells within a duct that is more than two, but not more than four, cells in depth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"     5",
"    </a>",
"    ]. The epithelial cells do not cross the lumen of the involved space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROLIFERATIVE BREAST LESIONS WITHOUT ATYPIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proliferative lesions without atypia include usual ductal hyperplasia, intraductal papillomas, sclerosing adenosis, radial scars and fibroadenomas. These lesions are associated with a small increased risk of developing breast cancer, approximately 1.5 to 2 times that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/2-5,8,9,12-15\">",
"     2-5,8,9,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibroadenomas are included in this category, but it is important to note that the histologic features of the fibroadenoma influence the risk of breast cancer. The risk of subsequent breast cancer is slightly elevated only if the fibroadenoma is complex, if there is adjacent proliferative disease or if there is a family history of breast cancer. For the majority of women with simple fibroadenomas, there is no increased risk of developing breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/2-5,12\">",
"     2-5,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Usual ductal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductal hyperplasia without atypia is a pathologic diagnosis, usually found as an incidental finding on biopsy of mammographic abnormalities or breast masses, characterized by an increased number of cells within the ductal space. Although the cells vary in size and shape, they retain the cytological features of benign cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. No additional treatment is needed for ductal hyperplasia. The risk of subsequent breast cancer in women with usual ductal hyperplasia is small and chemoprevention is not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intraductal papillomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary intraductal papillomas may be identified as a mass on a mammogram (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83703 \" href=\"UTD.htm?16/60/17351\">",
"     image 1",
"    </a>",
"    ), ultrasound (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83702 \" href=\"UTD.htm?37/1/37909\">",
"     image 2",
"    </a>",
"    ), MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85531 \" href=\"UTD.htm?35/44/36544\">",
"     image 3",
"    </a>",
"    ), ductogram [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/16\">",
"     16",
"    </a>",
"    ], or incidental [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/17\">",
"     17",
"    </a>",
"    ]. Nipple discharge is a frequent clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Solitary papillomas consist of a monotonous array of papillary cells that grow from the wall of a cyst into its lumen. Solitary papillomas can harbor areas of atypia or ductal carcinoma in situ (DCIS). Although there is some debate in the literature, the standard management of papillomas diagnosed by CNB is surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/14,18-23\">",
"     14,18-23",
"    </a>",
"    ]. In a metaanalysis of 34 studies that included 2236 nonmalignant breast papillary lesions diagnosed by CNB, 346 nonmalignant papillomas (15.7 percent) were upgraded to malignancy following a surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of malignancy is even higher when the papilloma contains atypical cells (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Management of atypical lesions on core biopsy results'",
"    </a>",
"    below). However, if an intraductal papilloma is incidental and &le;2 mm, an excision may not be necessary. In a retrospective review of 36 patients who underwent a core breast biopsy for calcifications or a mass and an intraductal papilloma was identified incidental to the mammographic finding, no cancers were identified in 14 patients who underwent an excision [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/17\">",
"     17",
"    </a>",
"    ]. The remaining 24 patients were radiographically stable for over 12 months. Larger studies should be performed to determine if no excision can be recommended for incidental intraductal papillomas.",
"   </p>",
"   <p>",
"    Once the diagnosis of solitary papilloma is confirmed by excisional biopsy, no additional treatment is needed. Unless there is associated atypia, there is no increased risk of subsequent breast cancer. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Atypical hyperplasia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Multiple papillomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse papillomatosis (multiple papillomas) may present as breast masses, nodules on ultrasound, or may be the cause of nipple discharge and can be seen on ductography. Diffuse papillomatosis is defined as a minimum of five papillomas within a localized segment of breast tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. After excision, additional treatment is not needed for diffuse papillomatosis. The risk of subsequent breast cancer in women with diffuse papillomatosis is small and chemoprevention is not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sclerosing adenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosing adenosis is a lobular lesion with increased fibrous tissue and interspersed glandular cells. It can present as a mass or a suspicious finding on mammogram [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. No treatment is needed for sclerosing adenosis. The risk of subsequent breast cancer in this population is small and chemoprevention is not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radial scars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial scars, also called complex sclerosing lesions, are a pathologic diagnosis, usually discovered incidentally when a breast mass or radiologic abnormality is removed or biopsied. Occasionally, radial scars are large enough to be detected by mammography, which cannot reliably differentiate between these lesions and spiculated carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Radial scars are characterized microscopically by a fibroelastic core with radiating ducts and lobules.",
"   </p>",
"   <p>",
"    There is ongoing controversy about the need for surgical excision when radial scars are found on core biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. We suggest that these be excised since most series show that 8 to 17 percent of surgical specimens at subsequent excision are positive for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. In addition to the possibility of finding an unrecognized in situ or invasive component, there is some evidence that radial scars may be premalignant lesions, meaning that they can slowly progress from scar to hyperplasia to carcinoma over time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No additional treatment beyond excision is needed for radial scars. The risk of subsequent breast cancer after excision in this population is small and chemoprevention is not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Simple fibroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple fibroadenomas are benign solid tumors containing glandular as well as fibrous tissue. In 20 percent of cases, multiple fibroadenomas occur in the same breast or bilaterally. The etiology of fibroadenomas is not known but a hormonal relationship is likely since they persist during the reproductive years, can increase in size during pregnancy or with estrogen therapy, and usually regress after menopause. They are most commonly found in women between the ages of 15 and 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although originally classified as nonproliferative lesions, fibroadenomas are now considered proliferative breast lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/12\">",
"     12",
"    </a>",
"    ]. However, it is important to note that the histologic features of the fibroadenoma influence the risk of breast cancer. The risk of subsequent breast cancer is slightly elevated only if the fibroadenoma is complex, if there is adjacent proliferative disease or if there is a family history of breast cancer. For the majority of women with simple fibroadenomas, there is no increased risk of developing breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/2-5,12\">",
"     2-5,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibroadenomas usually present as a well-defined, mobile mass on physical examination or a well-defined solid mass on ultrasound. A well-defined solid mass with benign imaging features can be managed with core needle biopsy or short-term (three to six months) follow-up with a repeat ultrasound and breast examination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/40\">",
"     40",
"    </a>",
"    ]. Definitive diagnosis can only be confirmed with a core biopsy or excision.",
"   </p>",
"   <p>",
"    It is not necessary to excise all biopsy proven fibroadenomas. Disadvantages of excisional surgery include scarring at the incision site, dimpling of the breast from the removal of the tumor, damage to the breast's duct system, and mammographic changes (eg, architectural distortion, skin thickening, increased focal density). If a biopsy proven fibroadenoma is asymptomatic, then it can be left in place, although some women wish to have the mass excised so that they will not worry further.",
"   </p>",
"   <p>",
"    Cryoablation is an alternative to surgical excision of fibroadenomas, but should only be considered after a core biopsy diagnosis of fibroadenoma has been made [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. A multicenter trial of 50 patients who underwent office-based cryoablation under ultrasound guidance reported the lesions tended to disappear progressively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/42\">",
"     42",
"    </a>",
"    ] and 75 percent were not palpable at 12 months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/43\">",
"     43",
"    </a>",
"    ]. Transient side effects included ecchymosis, local swelling, and discomfort that lasted as long as a few weeks after treatment. Percutaneous vacuum-assisted ultrasound-guided excision is another alternative to open excision technique for removal of fibroadenomas, but may be less effective for lesions &gt;2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a presumed fibroadenoma increases in size or is symptomatic, then excision is mandated to rule out malignant change and confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/41,42,46\">",
"     41,42,46",
"    </a>",
"    ]. Rapid growth of a lesion raises the suspicion for a phyllodes tumor, unusual fibroepithelial tumors which require more extensive surgical resection and in some cases may require radiation treatment as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ATYPICAL HYPERPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical hyperplasia (AH) includes both ADH and ALH. AH is a pathologic diagnosis, usually found as an incidental finding on biopsy of mammographic abnormalities or breast masses. These lesions have some, but not all, of the features of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical ductal hyperplasia &ndash; Atypical ductal hyperplasia (ADH) is characterized by a proliferation of uniform epithelial cells with monomorphic round nuclei filling part but not the entire involved duct.",
"      <br/>",
"      <br/>",
"      ADH shares some of the cytologic and architectural features of low-grade ductal carcinoma in situ (DCIS) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"       \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atypical lobular hyperplasia &ndash; Atypical lobular hyperplasia (ALH) is characterized by monomorphic, evenly spaced, dyshesive cells filling part, but not all, of the involved lobule. ALH can also involve ducts.",
"      <br/>",
"      <br/>",
"      ALH shares some of the cytologic and architectural features of lobular carcinoma in situ (LCIS) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Atypical hyperplasias (ADH and ALH), especially multifocal lesions, confer a substantial increase in the risk of subsequent breast cancer (relative risk 3.7 to 5.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/3,4,7,13,47\">",
"     3,4,7,13,47",
"    </a>",
"    ]. AH is associated with an increased risk of both ipsilateral and contralateral breast cancer and thus provides evidence of underlying breast abnormalities that predispose to breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/4\">",
"     4",
"    </a>",
"    ]. In a report from the Nurses' Health Study, only 56 percent of cancers that developed in women with AH occurred in the ipsilateral breast [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/48\">",
"     48",
"    </a>",
"    ]. The cumulative incidence of breast cancer over 30 years approached 35 percent.",
"   </p>",
"   <p>",
"    Some studies have shown that the risk of developing breast cancer is higher with ALH than ADH, however the data on this are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/13,47-49\">",
"     13,47-49",
"    </a>",
"    ]. There is a higher risk of subsequent breast cancer when the ALH involves both lobules and ducts (relative risk 6.8) as compared to lobules alone (relative risk 4.3) or ducts alone (2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the effect of family history of breast cancer in women with atypical hyperplasia are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/51\">",
"     51",
"    </a>",
"    ]. Several studies showed that a family history of breast cancer substantially increased the breast cancer risk in women with AH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/4,49\">",
"     4,49",
"    </a>",
"    ]. However, subsequent studies have not confirmed this and did not show that a family history further increased the breast cancer risk in women with AH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/4,47,51\">",
"     4,47,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk reduction strategies for women with atypical hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with AH should be counseled regarding risk reduction strategies. Ongoing surveillance with yearly mammography and twice-yearly breast exams is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/2,3,8,9,12-14\">",
"     2,3,8,9,12-14",
"    </a>",
"    ]. Women with AH should stop taking oral contraceptives, avoid hormone replacement therapy, and make appropriate lifestyle and dietary changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Primary prevention with the selective estrogen receptor modulators",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , or an aromatase inhibitor may be considered in women with AH for breast cancer risk reduction, although the benefits and risks must be discussed thoroughly. The Gail model incorporates atypical proliferative disease into a risk calculation that can be used to identify women who are appropriate candidates for primary prevention of breast cancer. The tool can be accessed online at",
"    <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/\">",
"     www.cancer.gov/bcrisktool/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The topics of breast cancer risk assessment and risk reduction are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"     \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FLAT EPITHELIAL ATYPIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flat epithelial atypia is a separate entity from ADH or ALH. Flat epithelial atypia is sometimes referred to as columnar cell change with atypia or columnar cell hyperplasia with atypia. Typically, flat epithelial atypia is diagnosed on breast biopsies done for calcifications found on screening mammograms. The relationship between flat epithelial atypia and cancer is still being defined, but the available data suggest that the risk of local recurrence or progression to invasive cancer is low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link&amp;anchor=H20980664#H20980664\">",
"     \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\", section on 'Flat epithelial atypia (FEA)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ATYPICAL LESIONS ON CORE BIOPSY RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the core needle biopsy (CNB) identifies an abnormality, such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), flat epithelial atypia, lobular carcinoma in situ (LCIS), papilloma, complex sclerosing adenosis or radial scar, a surgical excision should be performed to avoid underestimation of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/54-60\">",
"     54-60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Proliferative breast lesions without atypia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon retrospective reviews, analysis of a larger tissue sample removed by a surgical excision results in an upgrade in diagnosis from atypia to ductal carcinoma in situ (DCIS) or invasive breast cancer in 10 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/54,59-64\">",
"     54,59-64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link&amp;anchor=H1202095003#H1202095003\">",
"     \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\", section on 'Surgical management of AH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, an intraductal papilloma with atypia diagnosed by CNB is associated with a high underestimation of malignancy. In the metaanalysis previously described where a surgical excision was performed following a CNB, atypical papillary lesions were significantly more likely to be associated with malignancy compared with papillary lesions without atypia (36.9 versus 7.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Intraductal papillomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS LESIONS OF THE BREAST",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lipoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast lipomas are benign, usually solitary tumors composed of mature fat cells. These present as soft, nontender, well-circumscribed masses. Clinically, it is sometimes difficult to distinguish lipomas from other conditions; the diagnosis can be confirmed with a core or excisional biopsy. Core biopsies are somewhat problematic for lipomas, as it is difficult to be certain that the diagnosis is concordant, and lipomas should be surgically excised if they cause diagnostic confusion, continue to enlarge, or grow rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/6\">",
"     6",
"    </a>",
"    ]. For smaller lesions, excisional biopsy is often preferable. There is no increased risk of subsequent breast cancer associated with lipomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fat necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat necrosis of the breast is a benign condition that most commonly occurs as the result of breast trauma or surgical intervention. Fat necrosis can be confused with a malignancy on physical examination and may mimic malignancy on radiologic studies. It is sometimes necessary to biopsy these lesions to confirm the diagnosis, although experienced radiologists can usually determine that a lesion represents fat necrosis based on mammographic and ultrasound findings such as oil cysts (collections of liquefied fat) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/6,65\">",
"     6,65",
"    </a>",
"    ]. Once the diagnosis is established, excision is not necessary and there is no increased risk of subsequent breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Giant fibroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant fibroadenomas refer to histologically typical fibroadenomas over 10 cm in size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"     5",
"    </a>",
"    ]. Excision is recommended. The primary challenge for the pathologist is to differentiate these from phyllodes tumors. Phyllodes tumors have a more cellular stromal component than fibroadenomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Juvenile fibroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile fibroadenomas are distinguished from adult fibroadenomas by exhibiting more glandularity and greater stromal cellularity. They occur in young women between the ages of 10 and 18 and vary in size from 5 to 20 cm in diameter. These usually painless, solitary, unilateral masses grow rapidly. Excision is recommended, but there is a risk of damage to the breast bud in prepubertal girls, and this should be discussed with the patient and family [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5,66\">",
"     5,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Complex fibroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex fibroadenomas present as a mass on physical examination or a nodule on mammogram or ultrasound. However, on pathology, these contain other proliferative changes, such as sclerosing adenosis, duct epithelial hyperplasia, epithelial calcification, or papillary apocrine changes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/67\">",
"     67",
"    </a>",
"    ]. They are associated with a slightly increased risk of cancer when multicentric proliferative changes are present in the surrounding glandular tissue.",
"   </p>",
"   <p>",
"    Appropriate management of complex fibroadenomas is controversial. While some believe that complex fibroadenomas warrant complete removal for histological examination, others suggest that they can be managed conservatively following core biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/67\">",
"     67",
"    </a>",
"    ]. In one series of 401 fibroadenomas, 63 (15.7 percent) were considered complex. At a mean follow-up of two years, invasive carcinoma was found in only one of the 63 patients with complex fibroadenomas; her initial core biopsy had shown atypical lobular hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diabetic mastopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic mastopathy, also known as lymphocytic mastitis or lymphocytic mastopathy, is seen occasionally in premenopausal women who have longstanding type 1 diabetes mellitus. The typical presentation is a suspicious breast mass with a dense mammographic pattern. Core biopsy is recommended for diagnostic confirmation. Pathology shows dense keloid-like fibrosis and periductal, lobular, or perivascular lymphocytic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. The pathogenesis is unknown, but it may represent an autoimmune reaction as the histologic features are similar to those seen in other autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/71\">",
"     71",
"    </a>",
"    ]. Once the diagnosis is established, excision is not necessary and there is no increased risk of subsequent breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Galactocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactoceles (milk retention cysts) are cystic collections of fluid, usually caused by an obstructed milk duct. These present as soft cystic masses on physical exam. At mammography, galactoceles may appear as an indeterminate mass, unless the classic fat-fluid level is seen. Ultrasound may show a complex mass. Diagnosis can be made based on the clinical history and aspiration, which yields a milky substance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/72\">",
"     72",
"    </a>",
"    ]. Once diagnosis is established, excision is not necessary and there is no increased risk of subsequent breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"     \"Common problems of breastfeeding and weaning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hamartoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hamartomas are benign lesions, also known as fibroadenolipoma, lipofibroadenoma, or adenolipoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/73\">",
"     73",
"    </a>",
"    ]. Hamartomas have varying amounts of glandular, adipose, and fibrous tissue. They present as discrete, encapsulated, painless masses, or are found incidentally on screening mammography. The diagnosis can be difficult to make with limited tissue, as hamartomas do not have specific diagnostic features. Fine needle aspiration and core needle biopsy are not sufficient to establish the diagnosis. As coexisting malignancy can occur; excision is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomas are pure epithelial neoplasms of the breast. They are distinguished from fibroadenomas by their sparse stromal elements. Adenomas are divided into two main groups: tubular and lactating adenomas. Lactating adenomas occur commonly in pregnancy. They are well circumscribed and lobulated. Although they may require excision because of their size, they do not have malignant potential [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Idiopathic granulomatous mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic granulomatous mastitis (IGM) is an inflammatory mass in the breast. The symptoms and radiologic findings may be mistaken for nonpuerperal mastitis, a breast abscess, or most often, carcinoma. Biopsy is necessary to make a diagnosis. IGM is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=see_link\">",
"     \"Erythematous disorders of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pseudoangiomatous stromal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoangiomatous stromal hyperplasia (PASH) is a benign stromal proliferation that simulates a vascular lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/5\">",
"     5",
"    </a>",
"    ]. PASH may present as a mass or thickening on physical examination. The most common appearance on mammography and ultrasound is a solid, well-defined, noncalcified mass [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic histologic appearance is a pattern of slit-like spaces in the stroma between glandular units [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/75\">",
"     75",
"    </a>",
"    ]. PASH can be confused with mammary angiosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/6,76\">",
"     6,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there are any suspicious features on imaging, the diagnosis of PASH on a core biopsy should not be accepted as a final diagnosis, and excisional biopsy should be performed. However, in the absence of suspicious imaging characteristics, a diagnosis of PASH at core biopsy is considered sufficient, and surgical excision is not always necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/77\">",
"     77",
"    </a>",
"    ]. There is no increased risk of subsequent breast cancer associated with PASH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast symptomatology in sarcoidosis is rare and seen primarily in patients with systemic involvement. Sarcoidosis of the breast presents as firm hard masses, mimicking carcinoma. The mammographic appearance is also suspicious with irregular, ill-defined, spiculated masses that are solid on ultrasound. Biopsy is needed for confirmation of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11081/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. There is no increased risk of subsequent breast cancer associated with sarcoidosis of the breast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     NIPPLE DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discharge is considered pathologic if it is spontaneous, persistent, or arises from a single duct. It is also pathologic if the discharge contains gross or occult blood. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     BREAST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast pain is classified as cyclical (ie, related to the menstrual cycle), noncyclical, or extramammary. Breast cancer may present as breast pain, thus a full evaluation is indicated. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=see_link\">",
"     \"Breast pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       \"Patient information: Common breast problems (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign breast lesions can be classified into three categories based on histologic findings: nonproliferative, proliferative without atypia, and atypical hyperplasias. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification of benign breast lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonproliferative lesions are not associated with an increased risk of breast cancer. Management is directed at making a definitive diagnosis and providing relief of symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonproliferative breast lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proliferative disease without atypia is associated with a small increased risk of subsequent breast cancer. Once the diagnosis is established, no additional treatment is indicated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Proliferative breast lesions without atypia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical ductal hyperplasia and atypical lobular hyperplasia are associated with a substantial increase in risk of subsequent breast cancer. Women with atypical hyperplasia should be closely monitored and counseled regarding risk reduction strategies. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Atypical hyperplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a proliferative breast lesion identified on core needle biopsy, such as atypical hyperplasia, lobular carcinoma in situ (LCIS), or an intraductal papilloma, we perform a surgical excision to avoid underestimation of a malignant diagnosis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of atypical lesions on core biopsy results'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"       \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/1\">",
"      Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 2003; 27:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/2\">",
"      London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/3\">",
"      Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/4\">",
"      Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353:229.",
"     </a>",
"    </li>",
"    <li>",
"     Schnitt, SJ, Collins, LC. Pathology of benign breast disorders. In: Breast diseases, 4th ed, Harris, JR, et al (Eds), Lippincott, Philadelphia 2010. p69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/6\">",
"      Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. Oncologist 2006; 11:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/7\">",
"      Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/8\">",
"      Is 'fibrocystic disease' of the breast precancerous? Arch Pathol Lab Med 1986; 110:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/9\">",
"      Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990; 66:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/10\">",
"      Worsham MJ, Abrams J, Raju U, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J 2007; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/11\">",
"      Love SM, Gelman RS, Silen W. Sounding board. Fibrocystic \"disease\" of the breast--a nondisease? N Engl J Med 1982; 307:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/12\">",
"      Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994; 331:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/13\">",
"      Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982; 49:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/14\">",
"      Ciatto S, Andreoli C, Cirillo A, et al. The risk of breast cancer subsequent to histologic diagnosis of benign intraductal papilloma follow-up study of 339 cases. Tumori 1991; 77:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/15\">",
"      Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997; 6:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/16\">",
"      Woods ER, Helvie MA, Ikeda DM, et al. Solitary breast papilloma: comparison of mammographic, galactographic, and pathologic findings. AJR Am J Roentgenol 1992; 159:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/17\">",
"      Jaffer S, Bleiweiss IJ, Nagi C. Incidental Intraductal Papillomas (&lt;2&nbsp;mm) of the Breast Diagnosed on Needle Core Biopsy do not Need to be Excised. Breast J 2013; 19:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/18\">",
"      Lewis JT, Hartmann LC, Vierkant RA, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol 2006; 30:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/19\">",
"      Valdes EK, Feldman SM, Boolbol SK. Papillary lesions: a review of the literature. Ann Surg Oncol 2007; 14:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/20\">",
"      Mercado CL, Hamele-Bena D, Oken SM, et al. Papillary lesions of the breast at percutaneous core-needle biopsy. Radiology 2006; 238:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/21\">",
"      Sydnor MK, Wilson JD, Hijaz TA, et al. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology 2007; 242:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/22\">",
"      Ahmadiyeh N, Stoleru MA, Raza S, et al. Management of intraductal papillomas of the breast: an analysis of 129 cases and their outcome. Ann Surg Oncol 2009; 16:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/23\">",
"      Wen X, Cheng W. Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors. Ann Surg Oncol 2013; 20:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/24\">",
"      Ali-Fehmi R, Carolin K, Wallis T, Visscher DW. Clinicopathologic analysis of breast lesions associated with multiple papillomas. Hum Pathol 2003; 34:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/25\">",
"      Wang J, Costantino JP, Tan-Chiu E, et al. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 2004; 96:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/26\">",
"      Jensen RA, Page DL, Dupont WD, Rogers LW. Invasive breast cancer risk in women with sclerosing adenosis. Cancer 1989; 64:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/27\">",
"      Mitnick JS, Vazquez MF, Harris MN, Roses DF. Differentiation of radial scar from scirrhous carcinoma of the breast: mammographic-pathologic correlation. Radiology 1989; 173:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/28\">",
"      Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med 1999; 340:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/29\">",
"      Sanders ME, Page DL, Simpson JF, et al. Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer 2006; 106:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/30\">",
"      Berg JC, Visscher DW, Vierkant RA, et al. Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat 2008; 108:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/31\">",
"      Crystal P, Sadaf A, Bukhanov K, et al. High-risk lesions diagnosed at MRI-guided vacuum-assisted breast biopsy: can underestimation be predicted? Eur Radiol 2011; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/32\">",
"      Sohn VY, Causey MW, Steele SR, et al. The treatment of radial scars in the modern era--surgical excision is not required. Am Surg 2010; 76:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/33\">",
"      Linda A, Zuiani C, Furlan A, et al. Radial scars without atypia diagnosed at imaging-guided needle biopsy: how often is associated malignancy found at subsequent surgical excision, and do mammography and sonography predict which lesions are malignant? AJR Am J Roentgenol 2010; 194:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/34\">",
"      Hayes BD, O'Doherty A, Quinn CM. Correlation of needle core biopsy with excision histology in screen-detected B3 lesions: the Merrion Breast Screening Unit experience. J Clin Pathol 2009; 62:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/35\">",
"      Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am 2000; 38:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/36\">",
"      Kennedy M, Masterson AV, Kerin M, Flanagan F. Pathology and clinical relevance of radial scars: a review. J Clin Pathol 2003; 56:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/37\">",
"      Patterson JA, Scott M, Anderson N, Kirk SJ. Radial scar, complex sclerosing lesion and risk of breast cancer. Analysis of 175 cases in Northern Ireland. Eur J Surg Oncol 2004; 30:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/38\">",
"      Manfrin E, Remo A, Falsirollo F, et al. Risk of neoplastic transformation in asymptomatic radial scar. Analysis of 117 cases. Breast Cancer Res Treat 2008; 107:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/39\">",
"      Carty NJ, Carter C, Rubin C, et al. Management of fibroadenoma of the breast. Ann R Coll Surg Engl 1995; 77:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/40\">",
"      Harvey JA, Nicholson BT, Lorusso AP, et al. Short-term follow-up of palpable breast lesions with benign imaging features: evaluation of 375 lesions in 320 women. AJR Am J Roentgenol 2009; 193:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/41\">",
"      Littrup PJ, Freeman-Gibb L, Andea A, et al. Cryotherapy for breast fibroadenomas. Radiology 2005; 234:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/42\">",
"      Kaufman CS, Bachman B, Littrup PJ, et al. Office-based ultrasound-guided cryoablation of breast fibroadenomas. Am J Surg 2002; 184:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/43\">",
"      Kaufman CS, Littrup PJ, Freman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas: 12-month followup. J Am Coll Surg 2004; 198:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/44\">",
"      Whitworth PW, Rewcastle JC. Cryoablation and cryolocalization in the management of breast disease. J Surg Oncol 2005; 90:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/45\">",
"      Hung WK, Ying M, Chan CM, et al. Minimally invasive technology in the management of breast disease. Breast Cancer 2009; 16:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/46\">",
"      Grady I, Gorsuch H, Wilburn-Bailey S. Long-term outcome of benign fibroadenomas treated by ultrasound-guided percutaneous excision. Breast J 2008; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/47\">",
"      Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 2007; 25:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/48\">",
"      Collins LC, Baer HJ, Tamimi RM, et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer 2007; 109:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/49\">",
"      Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985; 55:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/50\">",
"      Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. Hum Pathol 1988; 19:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/51\">",
"      Collins LC, Baer HJ, Tamimi RM, et al. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. Cancer 2006; 107:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/52\">",
"      Schnitt SJ. The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance. Breast Cancer Res 2003; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     Schnitt, SJ, Collins. Columnar cell lesions and flat epithelial atypia of the breast. Seminars in Breast Disease 2005; 8:100. Available online at: www.seminarsinbreastdisease.com/article/S1092-4450(06)00035-4/abstract (Accessed on June 16. 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/54\">",
"      Margenthaler JA, Duke D, Monsees BS, et al. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg 2006; 192:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/55\">",
"      Chae BJ, Lee A, Song BJ, Jung SS. Predictive factors for breast cancer in patients diagnosed atypical ductal hyperplasia at core needle biopsy. World J Surg Oncol 2009; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/56\">",
"      Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005; 29:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/57\">",
"      Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006; 4:511.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/59\">",
"      Liberman L, Cohen MA, Dershaw DD, et al. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. AJR Am J Roentgenol 1995; 164:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/60\">",
"      Liberman L, Dershaw DD, Rosen PP, et al. Stereotaxic core biopsy of breast carcinoma: accuracy at predicting invasion. Radiology 1995; 194:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/61\">",
"      McGhan LJ, Pockaj BA, Wasif N, et al. Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy? Ann Surg Oncol 2012; 19:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/62\">",
"      Moore MM, Hargett CW 3rd, Hanks JB, et al. Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. Ann Surg 1997; 225:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/63\">",
"      Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology 2001; 218:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/64\">",
"      Winchester DJ, Bernstein JR, Jeske JM, et al. Upstaging of atypical ductal hyperplasia after vacuum-assisted 11-gauge stereotactic core needle biopsy. Arch Surg 2003; 138:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/65\">",
"      Soo MS, Kornguth PJ, Hertzberg BS. Fat necrosis in the breast: sonographic features. Radiology 1998; 206:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/66\">",
"      Wechselberger G, Schoeller T, Piza-Katzer H. Juvenile fibroadenoma of the breast. Surgery 2002; 132:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/67\">",
"      Sklair-Levy M, Sella T, Alweiss T, et al. Incidence and management of complex fibroadenomas. AJR Am J Roentgenol 2008; 190:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/68\">",
"      Lai EC, Chan WC, Ma TK, et al. The role of conservative treatment in idiopathic granulomatous mastitis. Breast J 2005; 11:454.",
"     </a>",
"    </li>",
"    <li>",
"     Gombos, EC, et al. Granulomatous mastitis. J Women's Imaging 2004; 6:136. Available online at: file://pt.wkhealth.com/pt/re/jwi/abstract.00130747-200409000-00007.htm;jsessionid=MYjWtpgRHShpwlk7Xl17dj8jK1Fm4b9kwQqnlGGzRpGrxBj1vVKc!1749550389!181195629!8091!-1 (Accessed on June 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/70\">",
"      Kudva YC, Reynolds C, O'Brien T, et al. \"Diabetic mastopathy,\" or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes. Diabetes Care 2002; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/71\">",
"      Lammie GA, Bobrow LG, Staunton MD, et al. Sclerosing lymphocytic lobulitis of the breast--evidence for an autoimmune pathogenesis. Histopathology 1991; 19:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/72\">",
"      Sabate JM, Clotet M, Torrubia S, et al. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics 2007; 27 Suppl 1:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/73\">",
"      Tse GM, Law BK, Ma TK, et al. Hamartoma of the breast: a clinicopathological review. J Clin Pathol 2002; 55:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/74\">",
"      Celliers L, Wong DD, Bourke A. Pseudoangiomatous stromal hyperplasia: a study of the mammographic and sonographic features. Clin Radiol 2010; 65:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/75\">",
"      Hoda SA, Rosen PP. Observations on the pathologic diagnosis of selected unusual lesions in needle core biopsies of breast. Breast J 2004; 10:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/76\">",
"      Salvador R, Lirola JL, Dom&iacute;nguez R, et al. Pseudo-angiomatous stromal hyperplasia presenting as a breast mass: imaging findings in three patients. Breast 2004; 13:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/77\">",
"      Hargaden GC, Yeh ED, Georgian-Smith D, et al. Analysis of the mammographic and sonographic features of pseudoangiomatous stromal hyperplasia. AJR Am J Roentgenol 2008; 191:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/78\">",
"      Sabat&eacute; JM, Clotet M, G&oacute;mez A, et al. Radiologic evaluation of uncommon inflammatory and reactive breast disorders. Radiographics 2005; 25:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11081/abstract/79\">",
"      Lower EE, Hawkins HH, Baughman RP. Breast disease in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 806 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11081=[""].join("\n");
var outline_f10_52_11081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF BENIGN BREAST LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NONPROLIFERATIVE BREAST LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Simple breast cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Papillary apocrine change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epithelial-related calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mild hyperplasia of the usual type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROLIFERATIVE BREAST LESIONS WITHOUT ATYPIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Usual ductal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intraductal papillomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Multiple papillomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sclerosing adenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radial scars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Simple fibroadenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ATYPICAL HYPERPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk reduction strategies for women with atypical hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FLAT EPITHELIAL ATYPIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF ATYPICAL LESIONS ON CORE BIOPSY RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MISCELLANEOUS LESIONS OF THE BREAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lipoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fat necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Giant fibroadenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Juvenile fibroadenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Complex fibroadenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diabetic mastopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Galactocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hamartoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Idiopathic granulomatous mastitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pseudoangiomatous stromal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      NIPPLE DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BREAST PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/806|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/60/17351\" title=\"diagnostic image 1\">",
"      Intraductal papilloma as a mammographic density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/1/37909\" title=\"diagnostic image 2\">",
"      Breast intraductal papilloma ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/44/36544\" title=\"diagnostic image 3\">",
"      Breast MRI intraductal papilloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=related_link\">",
"      Breast cysts: Clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=related_link\">",
"      Breast pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_52_11082="Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)";
var content_f10_52_11082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11082/contributors\">",
"     Anna Nowak-Wgrzyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11082/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/52/11082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/52/11082/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/52/11082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral allergy syndrome (OAS) is a relatively common form of food allergy, particularly in adults. It occurs in people who have pollen allergy, although not all patients have obvious hayfever or seasonal allergy symptoms. Patients typically report itching",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild swelling of the mouth and throat immediately following ingestion of certain uncooked fruits (including nuts) or raw vegetables. The symptoms result from contact urticaria in the oropharynx caused by pollen-related proteins in these foods. Only a small proportion of affected individuals experience systemic allergic reactions, although the disorder must be differentiated from more serious forms of food allergy.",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, clinical manifestations, and diagnosis of OAS and describes associations between specific pollens and foods. The pathogenesis, management, and prognosis of OAS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two terms are used to describe this type of allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1250202\">",
"    <span class=\"h3\">",
"     Oral allergy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term oral allergy syndrome (OAS) is widely recognized. However, it has been imprecisely applied in the literature to describe oropharyngeal reactions due to a variety of non-plant foods, as well as both oropharyngeal and systemic symptoms due to plant foods in subjects with pollen allergy. This imprecision has lead to considerable confusion. In this review, OAS is used to describe reactions caused by pollen-related foods that are",
"    <strong>",
"     limited to the oropharynx",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1250209\">",
"    <span class=\"h3\">",
"     Pollen-food allergy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms \"pollen-food allergy syndrome,\" \"pollen-food syndrome,\" and &ldquo;pollen-associated food allergy syndrome&rdquo; (all abbreviated PFAS) are increasingly used instead of OAS, both to emphasize the pathogenesis of these reactions, and to describe the full range of oropharyngeal and systemic symptoms that can occur in response to pollen-related foods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In this review, PFAS is the preferred term for the entire spectrum of reactions caused by pollen-related plant foods.",
"   </p>",
"   <p>",
"    Non-plant foods, such as cow's milk, egg, or seafood, do not cause oral allergy syndrome. Isolated oropharyngeal symptoms to foods that are not related to pollens may precede more severe systemic allergic reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of food allergy: An overview\", section on 'IgE-mediated reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of PFAS in the United States has not been reported, although it is probably the most common food allergy in adult subjects and there is a general impression that it has become more prevalent as respiratory allergy to pollen has increased over the past two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/4\">",
"     4",
"    </a>",
"    ]. Studies of prevalence include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In central Europe, it has been estimated that about 5 percent of the general population suffers from PFAS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 1272 Danish young adults (aged 22 years) used questionnaires, skin prick tests, and oral food challenges [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/6\">",
"       6",
"      </a>",
"      ]. Overall, 17 percent reported symptoms to pollen-associated foods (83 percent with oral symptoms), which represented 74 percent of those reporting possible pollen allergy.",
"     </li>",
"     <li>",
"      A systematic review of 36 population-based studies on prevalence of plant food allergies, with data from a total of over 250,000 children and adults, showed significant heterogeneity between studies regardless of food item or age group [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/7\">",
"       7",
"      </a>",
"      ]. Only six studies included food challenge tests with prevalences ranging from 0.1 percent to 4.3 percent each for fruits and tree nuts, 0.1 percent to 1.4 percent for vegetables, and &lt;1 percent each for wheat, soy, and sesame.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many adult patients with PFAS report symptoms beginning in childhood and there are certainly reports documenting that children are affected. As an example, in a group of 72 children (6 to 16 years) with severe rhinoconjunctivitis to birch pollen participating in a clinical trial of birch pollen immunotherapy, 93 percent reported symptoms upon ingestion of fruits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this was a highly select population and the prevalence of PFAS in more general populations of pollen-allergic children is not well studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for PFAS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sensitization to tree pollens (especially birch):",
"      </strong>",
"      Sensitization to tree pollens, and specifically birch pollen, is associated with the highest rates of PFAS. Allergy to grass pollens and weed pollens (commonly ragweed or mugwort) are less commonly associated with PFAS. In a population of 936 unselected adults, for example, 24 percent were sensitized to pollen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/9\">",
"       9",
"      </a>",
"      ]. Pollen-sensitized individuals were evaluated for PFAS with clinician supervised oral food challenges. Symptoms to cross-reacting foods were recorded in 24, 10, and 4 percent of subjects sensitized to birch, mugwort, and grass, respectively.",
"     </li>",
"     <li>",
"      <strong>",
"       Sensitization to multiple pollens",
"      </strong>",
"      : Individuals sensitized to multiple pollens are most likely to be affected by PFAS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the study described previously, 52 percent of people allergic to three pollens reacted to related foods [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an Italian study of children with allergy to grass pollen (mean age of eight years), PFAS was reported in 20 percent of those allergic to grass alone, and up to 46 percent of those sensitized to both grass and birch [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Having symptomatic pollinosis (nasal, ocular, or respiratory symptoms of pollen allergy):",
"      </strong>",
"      Patients with nasal, ocular, and respiratory symptoms of pollen allergy (pollinosis) are at greater risk for PFAS, compared to patients who are sensitized to pollen but have no symptoms. In one large study of pollen-sensitized patients, the odds ratio of a clinical reaction to pollen-related fruits and vegetables was four times higher among those with symptoms of pollinosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients with pollen allergy can often be identified based upon the history of suggestive symptoms during a known pollen season (",
"      <a class=\"graphic graphic_figure graphicRef74234 \" href=\"UTD.htm?26/61/27615\">",
"       figure 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Another study showed that adult birch-allergic patients with PFAS were more likely to have a longer duration of birch tree pollen allergy and asthma, compared to birch-allergic patients without PFAS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/10\">",
"       10",
"      </a>",
"      ]. Pollinosis usually precedes the development of PFAS by a number of years in adults.",
"     </li>",
"     <li>",
"      <strong>",
"       Living in areas where certain pollens are prevalent:",
"      </strong>",
"      Associations between pollen and plant foods are strongly affected by geographic location and indigenous flora. PFAS is more prevalent in areas where birch trees are common and the population demonstrates high levels of pollen-specific IgE (particularly to birch) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/10,12,13\">",
"       10,12,13",
"      </a>",
"      ]. Birch trees and birch pollinosis are common in central and northern Europe and northern Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Sensitization to birch pollen is very common in the United States, although birch trees are not particularly prevalent. This finding most likely reflects extensive homology among trees of the Fagales order such as birch, oak, alder, hazel, chestnut, and hornbeam [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common signs and symptoms are pruritus, tingling, mild erythema, and subtle angioedema of the lips, oral mucosa, palate, and throat, sometimes accompanied by a sensation of throat swelling. Symptoms occur while or shortly after (within five minutes of) ingesting the culprit fruit, nut, or vegetable. Oral papules or blisters are occasionally reported, although blisters or vesicles in isolation are not typical. Isolated oropharyngeal symptoms are reported by 75 to 95 percent of subjects with PFAS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms resolve promptly when the food is swallowed due to disruption of the structure of the allergen by gastric acid and proteolytic digestive enzymes.",
"   </p>",
"   <p>",
"    Particularly with fruits, patients may report that one variety of the food is more troublesome than another, or that the symptoms do not develop after every exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22906921\">",
"    <span class=\"h2\">",
"     Seasonal pollen allergies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have clinical symptoms of allergy (rhinitis, conjunctivitis, asthma) in response to pollen, as mentioned previously. Other patients may be sensitized to pollen but do not have clinical symptoms of seasonal allergy; these individuals can only be identified by objective testing for pollen sensitization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22907059\">",
"    <span class=\"h3\">",
"     Seasonal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PFAS is an IgE-mediated reaction, and symptoms may increase during or following the pollen season because of seasonal boosting of pollen-IgE levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8377411\">",
"    <span class=\"h3\">",
"     Impact of cooking",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, symptoms only develop in response to eating the raw, uncooked food. Patients usually tolerate the culprit food in various cooked forms. Cooking, baking, or even briefly microwaving raw fruits and vegetables is usually sufficient to alter the allergens that are responsible for PFAS. Tree nuts and peanuts are an important exception to this generalization, as roasted nuts can cause PFAS. Implications for management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link&amp;anchor=H17#H17\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Food avoidance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Double-blind, placebo-controlled food challenges (DBPCFC) with roasted hazelnuts (140 degrees C, 40 min) were performed in 17 birch pollen-allergic patients with DBPCFC-confirmed food allergy to raw hazelnuts. Challenge with roasted nuts was positive in 5 of 17 patients. The symptoms were generally mild and included OAS (oral allergy syndrome) in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/23\">",
"     23",
"    </a>",
"    ]. The allergens that cause PFAS are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 10 percent of patients with allergies to fresh fruits and vegetables experience systemic symptoms. A few patients complain of nausea and abdominal discomfort, which may represent esophageal and gastric symptoms that develop before the allergen is fully degraded. Some birch-allergic individuals develop analogous contact urticaria on their hands after handling raw potato. These two presentations are better classified as local reactions because the involved tissues are directly contacting the undigested food.",
"   </p>",
"   <p>",
"    True systemic reactions involve tissues that do not come into direct contact with undigested food. Symptoms may include the entire range of IgE-mediated allergic manifestations, such as urticaria, angioedema, nasal congestion, sneezing, flushing, wheezing, cough, diarrhea, and hypotension.",
"   </p>",
"   <p>",
"    In a review of several studies of patients with PFAS, which included a total of 1361 subjects, the following was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      9 percent experienced associated symptoms outside of the gastrointestinal tract",
"     </li>",
"     <li>",
"      3 percent at some time experienced systemic symptoms without oral symptoms",
"     </li>",
"     <li>",
"      1.7 percent experienced anaphylactic shock",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who react to plant foods but do not report allergic rhinitis (AR) in response to pollens are at higher risk for systemic reactions, because these patients may not be sensitized to pollen and may have an independent food allergy, rather than PFAS. In one study, 82 percent of patients with birch-related fruit allergy without AR had systemic symptoms, while only 45 percent of those with both fruit allergy and AR had systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/24\">",
"     24",
"    </a>",
"    ]. Anaphylactic shock occurred in 36 percent of those without AR, versus 9 percent of those with AR. The high rate of systemic reactions in the subjects with AR in this pre-selected population was unusual and probably not representative of a general population of patients with PFAS. A report of patients with severe hazelnut allergy without concomitant pollinosis documented IgE binding to heat-stable hazelnut proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, the sera from patients with PFAS to hazelnut and pollinosis did not bind to these heat-stable proteins.",
"   </p>",
"   <p>",
"    Certain foods have been associated with higher rates of systemic reactions, including peanuts, tree nuts, peach, and mustard. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1250309\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with any of the following characteristics should be referred to an allergy expert for further evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite or possible systemic symptoms. These patients should also be provided with one or more epinephrine autoinjectors. Instructions for prescribing epinephrine, as well as information for patients regarding the proper use of autoinjectors, are found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"       \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=see_link\">",
"       \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who report oropharyngeal symptoms but have no history of seasonal allergic symptoms to suggest pollen allergy, since these patients may have a primary food allergy. (See",
"      <a class=\"local\" href=\"#H26941174\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with reactions to foods that carry a higher risk of systemic reactions, such as peanuts, tree nuts, and mustard. In addition, peach is associated with systemic reactions in the Mediterranean region, due to the LTP sensitization. The rates of systemic reactions to peach in other regions of the world are not known but are likely lower than in the Mediterranean region.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POLLEN-FOOD ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fruit and vegetable allergens are highly conserved proteins that demonstrate homology to proteins found throughout the plant world. This homology results in associations among pollens and plant foods (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As stated previously, the plant foods that cause PFAS can also cause independent food allergies (without pollen sensitization), which are associated with higher rates of systemic reactions. The allergens responsible for various types of reactions and the evaluation of patients with systemic reactions are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Foods associated with tree pollens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26942027\">",
"    <span class=\"h3\">",
"     Birch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients allergic to birch pollen may develop oral symptoms after ingestion of the following plant foods (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fruits and tree nuts in the Rosaceae and Betulaceae families: apple, peach, apricot, cherry, and plum, pear, almond, and hazelnut [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vegetables and spices in the Apiaceae family: carrot, celery, parsley, caraway, fennel, coriander, and aniseed",
"     </li>",
"     <li>",
"      Legumes in the Fabaceae family: soybean and peanut [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sensitized to the pollen of the plane tree (aka Sycamore) may react to hazelnut, fruits such as peach, apple, kiwi, peanut, corn, chickpea, lettuce, and green beans [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Foods associated with weed pollens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26942058\">",
"    <span class=\"h3\">",
"     Ragweed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sensitized to ragweed pollen may react to the following plant foods (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melons and vegetables in the Cucurbitaceae family: cantaloupe, honeydew, watermelon, zucchini, cucumber",
"     </li>",
"     <li>",
"      Bananas (the Musaceae family)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mugwort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sensitized to mugwort pollen may react to the following plant foods (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vegetables and spices in the Apiaceae family: carrot, celery, parsley, caraway, fennel, coriander, and aniseed",
"     </li>",
"     <li>",
"      Bell pepper, black pepper, garlic, and onion (various plant families)",
"     </li>",
"     <li>",
"      Vegetables and spices in the Cruciferae family: mustard, cauliflower, cabbage, and broccoli",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6344447\">",
"    <span class=\"h2\">",
"     Foods associated with grass pollen (timothy, orchard)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grass pollen-food cross-reactivity is not as well-described as tree pollen and weed pollen-food cross-reactivity, so it may occur less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Patients sensitized to grass pollen may react to the following plant foods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melons (Cucurbitaceae family)",
"     </li>",
"     <li>",
"      White potato and tomato (Solanaceae family)",
"     </li>",
"     <li>",
"      Orange (Rutaceae)",
"     </li>",
"     <li>",
"      Swiss chard (Amaranthaceae)",
"     </li>",
"     <li>",
"      Peanut (Fabaceae)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Specific syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain types of PFAS are associated with more severe reactions. Several of these have been recognized as specific syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Celery-mugwort-spice syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially severe allergic reactions may be seen in celery-allergic patients who are sensitized to both birch and mugwort. This is the &ldquo;celery-spice-carrot-mugwort syndrome&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/2,34\">",
"     2,34",
"    </a>",
"    ]. In this syndrome, reactions to other foods of the Apiaceae family (carrot, caraway, parsley, fennel, coriander, and aniseed), as well as to paprika, pepper, mango, garlic, leek, and onion may be seen (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mugwort-mustard syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sensitized to mugwort (Artemisia vulgaris) may develop allergy to mustard and experience severe reactions (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among 38 adults with mustard allergy, 97 percent were sensitized to mugwort [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately 10 percent reported anaphylaxis. Those without anaphylactic events in the past underwent double-blind placebo-controlled food challenge (DBPCFC) with yellow mustard and 14 of 20 patients reacted: 11 had OAS and 3 had systemic symptoms. In addition, all patients were sensitized to other foods belonging to the Brassicaceae family (cauliflower, cabbage, broccoli) and 40 percent reported clinical symptoms upon ingestion of these foods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Latex-fruit syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to latex allergens, rather than pollen allergens, can also sensitize some individuals to plant foods. Approximately 30 to 50 percent of individuals who are allergic to natural rubber latex (NRL) show an associated hypersensitivity to some plant-derived foods, especially fresh fruits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/4\">",
"     4",
"    </a>",
"    ]. This is called latex-fruit, or latex-food, syndrome. An increasing number of plant foods, such as avocado, banana, chestnut, kiwi, peach, tomato, white potato, and bell pepper, have been associated with this syndrome (",
"    <a class=\"graphic graphic_figure graphicRef60713 \" href=\"UTD.htm?0/50/801\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. In one case series, up to 50 percent of the reported food reactions were anaphylactic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Latex-fruit syndrome is frequently included in the discussion of PFAS because of the analogous pathogenic mechanism. It is not always clear, however, whether latex sensitization precedes or follows the onset of food allergy, or which route of sensitization (skin, mucous membrane contact, or inhalation) underlies the condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Food-food associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also patterns of interactions among plant foods that may involve grouping of foods associated with various pollens. Only a few such groupings have been reported, but the clinician should be aware that the foods to which a patient with PFAS will react may not be easily predicted. As an example, patients who react to cantaloupe melon may also react to banana or watermelon, which would not be surprising, as each of these is related to ragweed pollen (",
"    <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"     figure 2",
"    </a>",
"    ). However, patients who react to cantaloupe may also react to peach, which is usually considered to be related to birch pollen. Note that some plant foods (eg, peach) have been included in more than one botanical family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Peach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peach may be associated with both OAS and systemic reactions. Approximately one-half of individuals allergic to peach will react to other birch-related fruits (",
"    <a class=\"graphic graphic_figure graphicRef79411 \" href=\"UTD.htm?9/46/9952\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Peach is one of the most frequent causes of food allergy in Europe, both in the northern regions and in Mediterranean areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Sensitization to peach and related Rosaceae fruits without clinical symptoms is also common, and sensitization alone is not sufficient to diagnose clinical allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peach allergy in Spain appears to be particularly prevalent and is associated with more systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/43\">",
"     43",
"    </a>",
"    ]. A digestion-stable lipid transfer protein has been implicated as a relevant allergen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Melons",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Northern America, the majority of patients reporting allergy to melons (Cucurbitaceae) (watermelon, cantaloupe, and honeydew) have weed pollen allergy and react clinically to at least one other related food (avocado, banana, kiwi, and peach) (",
"    <a class=\"graphic graphic_figure graphicRef79411 \" href=\"UTD.htm?9/46/9952\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/19,44,45\">",
"     19,44,45",
"    </a>",
"    ]. In contrast, in the central region of Spain, melon allergy is frequently associated with sensitization to several pollens, especially grass pollen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941090\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following components should be present to make the diagnosis of PFAS, although there are no established diagnostic criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of symptoms consistent with PFAS",
"     </li>",
"     <li>",
"      Evidence of allergic sensitization to the plant food in question",
"     </li>",
"     <li>",
"      Evidence of allergic sensitization to pollen",
"     </li>",
"     <li>",
"      A known correlation between the plant food(s) in question and a pollen(s) to which the patient is sensitized (",
"      <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941097\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any form of food allergy, the evaluation of PFAS combines a carefully gathered history, physical examination, objective testing for specific IgE to food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pollen, and possible oral food challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/21\">",
"     21",
"    </a>",
"    ]. All of these components may not be necessary in each case, and the extent of the evaluation, as well as the approach to management, is influenced by the food to which the patient reacted and the severity of the symptoms.",
"   </p>",
"   <p>",
"    Most diagnostic allergy procedures, especially skin testing and food challenges, should be performed by allergy specialists with training in the management of serious allergic reactions. In vitro tests for specific IgE may be performed by the non-specialist, although definitive interpretation may require a specialist's input.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941104\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important information obtained from the history includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Has the patient experienced oropharyngeal symptoms, systemic symptoms, or both? Patients with systemic symptoms should be thoroughly evaluated by an allergy specialist and provided with one or more epinephrine autoinjectors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link&amp;anchor=H16#H16\">",
"       \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Are symptoms of pollen allergy present? In many cases, pollen allergy (pollinosis) can be detected clinically as rhinitis, conjunctivitis, or asthma symptoms, which occur in a seasonal pattern (",
"      <a class=\"graphic graphic_figure graphicRef74234 \" href=\"UTD.htm?26/61/27615\">",
"       figure 1",
"      </a>",
"      ). If the patient does not have obvious symptoms of pollinosis, then testing for pollen sensitization should be performed.",
"     </li>",
"     <li>",
"      Has the patient reacted to other plant foods related to the one in question (",
"      <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"       figure 2",
"      </a>",
"      )? Patients may not recall reactions to foods they uncommonly eat unless specifically asked. A seven-item diagnostic questionnaire for PFAS has been validated in 110 adult subjects with tree pollen allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/47\">",
"       47",
"      </a>",
"      ]. It is a practical tool for identification of patients with PFAS.",
"     </li>",
"     <li>",
"      Are cooked forms of the food tolerated? The development of symptoms with raw foods but not with the cooked forms is very suggestive of PFAS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941111\">",
"    <span class=\"h2\">",
"     Objective testing for food allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to most patients with suspected PFAS is to test in parallel with both commercial extracts (when available) and prick-by-prick testing to fresh foods, except in the situations discussed below. (See",
"    <a class=\"local\" href=\"#H26941132\">",
"     'IgE immunoassays'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As in all forms of IgE-mediated food allergy, testing must be interpreted in the context of a careful clinical history. Both skin testing and in vitro testing in the diagnosis of PFAS are complicated by the variable and unstable nature of the responsible allergens and the extensive cross-reactivity among them. Both false negative and false positive results are common in patients with PFAS. Positive tests may result from the presence of cross-reactive panallergens in fruits and vegetables from the same family, as well as in plant foods and the related pollens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/42\">",
"     42",
"    </a>",
"    ]. However, these may not be the allergens responsible for the patient's symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941118\">",
"    <span class=\"h3\">",
"     Prick-by-prick skin testing with fresh foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred method of testing in most cases is skin prick testing (SPT) with fresh fruits and vegetables using the prick-by-prick technique. Prick-by-prick testing is performed by inserting the test device into the fruit, withdrawing it, and then immediately pricking the patient's cleaned skin. It is important to prick all edible parts of the food (eg, both the outer skin and the flesh of fruits) with the testing device in order to recreate the allergen exposure that would result from eating these foods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing with fresh fruits and vegetables is sometimes confounded by natural variations in allergen levels due to differences among the various varieties (eg, cultivars), ripeness, or changes induced by storage. Despite this, the prick-by-prick method is more sensitive than SPT with commercial extracts for most foods implicated in PFAS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the sensitivity of SPT using a commercial extract of apple was 2 percent, compared to 82 percent when prick-by-prick technique was used with fresh apple [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/48\">",
"     48",
"    </a>",
"    ]. The prick-by-prick technique also proved to be the more sensitive for carrot, celery, cherry, tomato, orange, and peach, although the difference was not as dramatic. Each of these plant foods contains unstable allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292433\">",
"    <span class=\"h3\">",
"     Commercial food extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercial extracts have low sensitivity for detecting sensitization to the allergens that are typically responsible for PFAS, because PFAS is usually caused by unstable allergens that tend to be destroyed during extract production [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this limitation, skin testing with commercial extracts may be useful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To evaluate for sensitization to tree nuts and legumes, such as peanut, hazelnut, and pea, which contain stable allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/48\">",
"       48",
"      </a>",
"      ]. Commercial extracts may be inadvertently enriched for stable allergens as a result of processing.",
"     </li>",
"     <li>",
"      To evaluate for sensitization to foods that might be difficult to prepare or irritating to the skin, such as spices.",
"     </li>",
"     <li>",
"      To help assess the risk of systemic reactions: individuals with positive skin tests to commercial Rosaceae food extracts were more likely to experience systemic reactions than those with positive skin tests only to fresh extracts (64 percent versus 6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/51\">",
"       51",
"      </a>",
"      ]. As mentioned previously, commercial extracts are often enriched for the stable allergens, which are associated with systemic reactions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"       \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941132\">",
"    <span class=\"h3\">",
"     IgE immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are clinical situations in which the most appropriate initial test for food-specific IgE is an in vitro immunoassay (which were previously called RAST tests). Examples include patients with a history of life-threatening anaphylaxis to a small amount of the implicated food, those with dermographism or extensive skin disease, those who cannot discontinue interfering medications, and those with unstable asthma. These issues are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgE immunoassays for various foods have not been systematically evaluated in the diagnosis of PFAS. The use of fresh food to coat the immunoassay disk has been used in some reports; however, this is impractical outside of research centers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941146\">",
"    <span class=\"h2\">",
"     Objective testing for pollen sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of pollen sensitization either by skin testing (most accurate) or by IgE immunoassays is necessary to make a conclusive diagnosis of PFAS. The performance and interpretation of skin testing for environmental allergies is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If skin testing is not available or not possible because the patient is taking interfering medications or for other reasons, then IgE immunoassays may be helpful in detecting sensitization to pollens. These are generally less sensitive than skin tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In reality, patients sometimes clearly describe symptoms of respiratory allergy during a specific pollen season, allowing for a reasonably certain diagnosis based solely on this history (",
"    <a class=\"graphic graphic_figure graphicRef74234 \" href=\"UTD.htm?26/61/27615\">",
"     figure 1",
"    </a>",
"    ). It may not be necessary to prove pollen sensitization if the patient's culprit food and seasonal symptoms match (ie, reactions to apple in a patient with rhinitis during tree pollen season) and if past reactions were consistently mild and limited to the oropharynx.",
"   </p>",
"   <p>",
"    However, pollen sensitization should be confirmed by testing if either of the following is true:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If it is unclear from the history that the patient has pollen allergy.",
"     </li>",
"     <li>",
"      If the patient has experienced systemic symptoms, because patients without pollen sensitization may have an isolated allergy to a plant food (unrelated to pollen) and be at higher risk for systemic reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941167\">",
"    <span class=\"h2\">",
"     Oral food challenges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PFAS will frequently have positive skin or in vitro tests to several related foods within a plant family, as mentioned above. However, as in other forms of IgE-mediated food allergy, positive tests do not necessarily predict clinical symptoms upon ingestion. Thus, oral food challenge remains the only definitive method of identifying clinical reactions.",
"   </p>",
"   <p>",
"    Although oral food challenges are the most conclusive means of confirming food allergy, challenges in PFAS may be impacted by some of the same issues that affect skin testing. Allergen levels can vary among cultivars, within different parts of the fruit (peel versus flesh), with ripeness, or due to changes induced by storage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/54\">",
"     54",
"    </a>",
"    ]. Challenge studies suggest that a history of clinical reactivity can be confirmed by oral food challenges in only one-third of melon-allergic patients, in two-thirds of patients allergic to fruits from Rosaceae family (peach, plum, pear, apple, almond, apricot, and strawberry), and in approximately 80 percent of patients allergic to fruits from Prunoideae family (peach, apricot, plum, and cherry) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/42,44,55\">",
"     42,44,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of obtaining a definitive diagnosis depends upon the severity of the reaction, nutritional needs, food preferences, and social issues. In many cases, diet is empirically limited based on the clinical history and the results of SPTs, rather than formal food challenges. However, food challenge may be indicated in certain situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with past systemic reactions to mixed foods, when the culprit food could not be unequivocally identified through skin or in vitro testing. In this case, the challenge would be performed in order to ascertain that the responsible food had been correctly identified.",
"     </li>",
"     <li>",
"      In patients reporting symptoms to a specific food, in whom testing failed to demonstrate sensitization to that food. Challenge would be done in this situation because testing may have been falsely negative due to allergen variability. (See",
"      <a class=\"local\" href=\"#H26941111\">",
"       'Objective testing for food allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom it is unclear if cooking or other processing eliminates the symptoms. Challenge can be performed with raw and cooked forms of the food.",
"     </li>",
"     <li>",
"      In patients with past systemic reactions to one food who have not been previously exposed to the related foods (eg, systemic reactions to hazelnut in a patient who has not eaten other tree nuts, or systemic reactions to peach in a patient who has not eaten other Rosaceae fruits).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In deciding on the challenge procedure (office versus hospital setting, intravenous access, the rate and quantity of administered food), risks should be assessed based on the severity of previous reactions, food involved, and test results. An open challenge with the food in its natural form should always follow a negative blinded challenge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special care is needed in preparing food for blinded challenges to confirm PFAS because freeze-drying, heating, and other processing methods can destroy the fragile allergens, leading to false negative results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/44\">",
"     44",
"    </a>",
"    ]. Standardized protocols for challenges to raw fruits and vegetables are not available, although research protocols for double-blind, placebo-controlled food challenges to fresh apple, peach, celery, carrot, and melon have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/29,42,44,56-59\">",
"     29,42,44,56-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941174\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that can mimic PFAS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An isolated food allergy (ie, primary food allergy) &mdash; Most of the foods that cause PFAS can also cause food allergy without pollen sensitization. Thus, the primary condition that must be differentiated from PFAS is an isolated allergy to the food in question. Any patient who does not have evidence of sensitization to pollens should be considered to have a primary food allergy and managed accordingly, including referral to an allergy expert, avoidance of all forms of the food (raw and cooked), and training in the use of epinephrine autoinjectors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"       \"Clinical manifestations of food allergy: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local irritation of the mouth, tongue, or throat caused by spicy, tart, or gritty foods. Examples include oral irritation from pineapple.",
"     </li>",
"     <li>",
"      Contact urticaria &mdash; Certain foods, such as tomato sauce, citrus fruit, garlic, and berries, can cause a local irritant contact urticaria of the lips and perioral skin. This condition is more common in children and would be suggested by the absence of pollen sensitization.",
"     </li>",
"     <li>",
"      Perioral dermatitis or oral contact dermatitis &mdash; Perioral dermatitis presents as small papules, vesicles,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tiny pustules with erythema and scaling located around the mouth, nose, or periorbital region. Perioral dermatitis can be caused by cosmetic products, or by contact with mango or cashews in individuals with a history of contact dermatitis in response to poison ivy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Contact dermatitis of the lips involves painful swelling or blistering of the lips, followed by peeling during resolution, which occurs over the course of days [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/62\">",
"       62",
"      </a>",
"      ]. The presence of persistent skin lesions distinguishes these conditions from OAS.",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease (GERD) &mdash; Patients with GERD can usually be distinguished clinically by less prominent oral symptoms or objectively, by the absence of sensitization to the food or related pollen in question. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilic esophagitis (EE) &mdash; EE can sometimes present with the sensation of food becoming lodged in the throat and may mimic PFAS and other forms of food allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Burning mouth syndrome &mdash; This disorder presents predominantly in middle aged and older women, and consists of an sensation of burning in the structures of the oral cavity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. Patients describe burning, rather than itching, but specific foods can sometimes exacerbate the symptoms, leading the patient to suspect an allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=see_link&amp;anchor=H10#H10\">",
"       \"Central craniofacial pain\", section on 'Burning mouth syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26941181\">",
"    <span class=\"h1\">",
"     FUTURE DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests using recombinant allergens are being developed, which could determine more precisely the allergens to which a patient is sensitized. In theory, these tests could distinguish individuals sensitized to labile antigens, such as Bet v 1 homologs or profilins, from those sensitized to heat and digestion-resistant antigens, and thus differentiate between PFAS and primary plant food allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link\">",
"     \"Future diagnostic tools for food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Component Resolved Diagnostics (CRD) detects IgE sensitization to the individual allergens (components) in the complex food. This technology represents a new direction in food allergy diagnosis. CRD may be especially helpful in distinguishing between cross-reactive allergens and primary sensitizing allergens, and in defining the risk for systemic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe reactions in patients with plant food allergy. CRD is commercially available in Europe and Japan; it is being evaluated by the FDA in the US. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H3#H3\">",
"       \"Future diagnostic tools for food allergy\", section on 'Technological advances'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Briefly, pollen-cross-reactive components (pathogenesis-related proteins-10 and profilins, such as peanut Ara h 8, hazelnut Cor a 1, soybean Gly m 4) in the plant foods are usually associated with mild oral symptoms, whereas stable components such as lipid transfer proteins (eg, hazelnut Cor a 8) and seed storage proteins (eg, peanut Ara h 1,2,3, soybean Gly m 5, 6 ) are more often associated with systemic reactions (",
"      <a class=\"graphic graphic_table graphicRef79719 \" href=\"UTD.htm?12/47/13048\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Basophil activation upon stimulation with allergen through binding to specific IgE on the surface of the cell is associated with expression of CD63. In vitro analysis of CD63 expression on basophils from birch pollen-allergic individuals with and without PFAS activated with apple extract and with purified recombinant major allergens from apple (Mal d 1), carrot (Dau c 1), and celery (Api g 1) showed specificity and sensitivity comparable to detection of specific allergen IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/52/11082/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H3#H3\">",
"       \"Future diagnostic tools for food allergy\", section on 'Technological advances'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnostic evaluation of food allergy\", section on 'In vitro testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral allergy syndrome (OAS) describes contact urticaria of the oropharynx upon ingestion of certain fresh fruits, nuts, or vegetables in individuals who are sensitized to plant pollens. Reactions are IgE-mediated and caused by allergens in plant foods that are homologous to pollen allergens. Pollen-food allergy syndrome (PFAS) is a more general term that encompasses both oropharyngeal and systemic reactions due to these allergens. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFAS is believed to be the most common type of food allergy in adults and likely affects at least 5 percent of the population. It is also seen in children, although the prevalence is not known. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients sensitized to tree pollen, and specifically birch pollen, have the highest rates of PFAS. Individuals with nasal, ocular, and respiratory symptoms in response to pollen are at greater risk for PFAS than pollen-sensitized subjects without clinical pollen allergy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFAS usually presents with pruritus and swelling of the mouth and throat during or just after ingestion of fresh, uncooked fruits and vegetables. Oropharyngeal symptoms usually resolve promptly when food is swallowed, and cooked forms of the culprit foods are generally tolerated because the responsible allergens are susceptible to gastric acid, digestive enzymes, and heat. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"       \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although uncommon, systemic symptoms and reactions to cooked foods are both possible in PFAS. Fewer than 10 percent of patients with PFAS experience systemic symptoms, although these may be severe. Peanuts, tree nuts, peaches, and mustard are associated with more systemic reactions than other foods. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Homology among protein allergens results in patterns of associations among fruits, vegetables, nuts, and pollens (",
"      <a class=\"graphic graphic_figure graphicRef60787 \" href=\"UTD.htm?16/1/16409\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79411 \" href=\"UTD.htm?9/46/9952\">",
"       figure 4",
"      </a>",
"      ). A similar phenomenon affects up to one-half of latex-allergic individuals and is called the latex-fruit syndrome (",
"      <a class=\"graphic graphic_figure graphicRef60713 \" href=\"UTD.htm?0/50/801\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pollen-food associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PFAS requires suggestive symptoms in a patient who has evidence of specific IgE to the food in question, accompanied by a clinical history of pollinosis or demonstrated sensitization to a pollen related to the culprit food. (See",
"      <a class=\"local\" href=\"#H26941090\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of patients suspected of having PFAS involves history, physical examination, objective testing for specific IgE to food",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pollen, and possible oral food challenge. Extensive evaluation may not be necessary if symptoms are mild and limited to the oropharynx. In contrast, any patient with systemic symptoms requires a thorough evaluation. (See",
"      <a class=\"local\" href=\"#H26941097\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirmation of pollen sensitization either by skin testing (most accurate) or by IgE immunoassays is necessary if it is unclear if the patient has pollen allergy, or if there were any systemic symptoms. Patients without pollen sensitization may have an isolated allergy to a plant food and therefore be at higher risk for systemic reactions. (See",
"      <a class=\"local\" href=\"#H26941146\">",
"       'Objective testing for pollen sensitization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral food challenge remains the only definitive diagnostic maneuver in some cases. In addition, challenge may be helpful for patients with past systemic symptoms who do not know if they tolerate cooked versions of the food or other closely related foods. (See",
"      <a class=\"local\" href=\"#H26941167\">",
"       'Oral food challenges'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/1\">",
"      Ma S, Sicherer SH, Nowak-Wegrzyn A. A survey on the management of pollen-food allergy syndrome in allergy practices. J Allergy Clin Immunol 2003; 112:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/2\">",
"      Egger M, Mutschlechner S, Wopfner N, et al. Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view. Allergy 2006; 61:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/3\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/4\">",
"      Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/5\">",
"      Kleine-Tebbe J, Herold DA. [Cross-reactive allergen clusters in pollen-associated food allergy]. Hautarzt 2003; 54:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/6\">",
"      Osterballe M, Mortz CG, Hansen TK, et al. The prevalence of food hypersensitivity in young adults. Pediatr Allergy Immunol 2009; 20:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/7\">",
"      Zuidmeer L, Goldhahn K, Rona RJ, et al. The prevalence of plant food allergies: a systematic review. J Allergy Clin Immunol 2008; 121:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/8\">",
"      M&ouml;ller C. Effect of pollen immunotherapy on food hypersensitivity in children with birch pollinosis. Ann Allergy 1989; 62:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/9\">",
"      Osterballe M, Hansen TK, Mortz CG, Bindslev-Jensen C. The clinical relevance of sensitization to pollen-related fruits and vegetables in unselected pollen-sensitized adults. Allergy 2005; 60:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/10\">",
"      Asero R, Massironi F, Velati C. Detection of prognostic factors for oral allergy syndrome in patients with birch pollen hypersensitivity. J Allergy Clin Immunol 1996; 97:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/11\">",
"      Ricci G, Righetti F, Menna G, et al. Relationship between Bet v 1 and Bet v 2 specific IgE and food allergy in children with grass pollen respiratory allergy. Mol Immunol 2005; 42:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/12\">",
"      Ebner C, Birkner T, Valenta R, et al. Common epitopes of birch pollen and apples--studies by western and northern blot. J Allergy Clin Immunol 1991; 88:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/13\">",
"      Asero R. Relevance of pollen-specific IgE levels to the development of Apiaceae hypersensitivity in patients with birch pollen allergy. Allergy 1997; 52:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/14\">",
"      Kazemi-Shirazi L, Pauli G, Purohit A, et al. Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. J Allergy Clin Immunol 2000; 105:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/15\">",
"      Vieths S, Scheurer S, Ballmer-Weber B. Current understanding of cross-reactivity of food allergens and pollen. Ann N Y Acad Sci 2002; 964:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/16\">",
"      Gotoda H, Maguchi S, Kawahara H, et al. Springtime pollinosis and oral allergy syndrome in Sapporo. Auris Nasus Larynx 2001; 28 Suppl:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/17\">",
"      Mari A, Wallner M, Ferreira F. Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4). Clin Exp Allergy 2003; 33:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/18\">",
"      Niederberger V, Pauli G, Gr&ouml;nlund H, et al. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998; 102:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/19\">",
"      Anderson LB Jr, Dreyfuss EM, Logan J, et al. Melon and banana sensitivity coincident with ragweed pollinosis. J Allergy 1970; 45:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/20\">",
"      Eriksson NE, Wihl JA, Arrendal H. Birch pollen-related food hypersensitivity: influence of total and specific IgE levels. A multicenter study. Allergy 1983; 38:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/21\">",
"      Ortolani C, Ispano M, Pastorello E, et al. The oral allergy syndrome. Ann Allergy 1988; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/22\">",
"      Ortolani C, Pastorello EA, Farioli L, et al. IgE-mediated allergy from vegetable allergens. Ann Allergy 1993; 71:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/23\">",
"      Hansen KS, Ballmer-Weber BK, L&uuml;ttkopf D, et al. Roasted hazelnuts--allergenic activity evaluated by double-blind, placebo-controlled food challenge. Allergy 2003; 58:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/24\">",
"      Fern&aacute;ndez-Rivas M, van Ree R, Cuevas M. Allergy to Rosaceae fruits without related pollinosis. J Allergy Clin Immunol 1997; 100:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/25\">",
"      Schocker F, L&uuml;ttkopf D, M&uuml;ller U, et al. IgE binding to unique hazelnut allergens: identification of non pollen-related and heat-stable hazelnut allergens eliciting severe allergic reactions. Eur J Nutr 2000; 39:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/26\">",
"      Ortolani C, Ballmer-Weber BK, Hansen KS, et al. Hazelnut allergy: a double-blind, placebo-controlled food challenge multicenter study. J Allergy Clin Immunol 2000; 105:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/27\">",
"      de Groot H, de Jong NW, Vuijk MH, Gerth van Wijk R. Birch pollinosis and atopy caused by apple, peach, and hazelnut; comparison of three extraction procedures with two apple strains. Allergy 1996; 51:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/28\">",
"      W&uuml;thrich B, St&auml;ger J, Johansson SG. Celery allergy associated with birch and mugwort pollinosis. Allergy 1990; 45:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/29\">",
"      Ballmer-Weber BK, Hoffmann A, W&uuml;thrich B, et al. Influence of food processing on the allergenicity of celery: DBPCFC with celery spice and cooked celery in patients with celery allergy. Allergy 2002; 57:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/30\">",
"      Mittag D, Vieths S, Vogel L, et al. Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens. J Allergy Clin Immunol 2004; 113:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/31\">",
"      Mittag D, Akkerdaas J, Ballmer-Weber BK, et al. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J Allergy Clin Immunol 2004; 114:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/32\">",
"      Vieths S. Allergenic cross-reactivity, food allergy and pollen. Environ Toxicol Pharmacol 1997; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/33\">",
"      Maeda N, Inomata N, Morita A, et al. Correlation of oral allergy syndrome due to plant-derived foods with pollen sensitization in Japan. Ann Allergy Asthma Immunol 2010; 104:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/34\">",
"      W&uuml;thrich B, Dietschi R. [The celery-carrot-mugwort-condiment syndrome: skin test and RAST results]. Schweiz Med Wochenschr 1985; 115:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/35\">",
"      Figueroa J, Blanco C, Dumpi&eacute;rrez AG, et al. Mustard allergy confirmed by double-blind placebo-controlled food challenges: clinical features and cross-reactivity with mugwort pollen and plant-derived foods. Allergy 2005; 60:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/36\">",
"      Garc&iacute;a Ortiz JC, Moyano JC, Alvarez M, Bellido J. Latex allergy in fruit-allergic patients. Allergy 1998; 53:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/37\">",
"      Blanco C, Carrillo T, Castillo R, et al. Latex allergy: clinical features and cross-reactivity with fruits. Ann Allergy 1994; 73:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/38\">",
"      Blanco C, Carrillo T, Castillo R, et al. Avocado hypersensitivity. Allergy 1994; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/39\">",
"      Brehler R, Theissen U, Mohr C, Luger T. \"Latex-fruit syndrome\": frequency of cross-reacting IgE antibodies. Allergy 1997; 52:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/40\">",
"      Nel A, Gujuluva C. Latex antigens: identification and use in clinical and experimental studies, including crossreactivity with food and pollen allergens. Ann Allergy Asthma Immunol 1998; 81:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/41\">",
"      Cuesta-Herranz J, L&aacute;zaro M, de las Heras M, et al. Peach allergy pattern: experience in 70 patients. Allergy 1998; 53:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/42\">",
"      Rodriguez J, Crespo JF, Lopez-Rubio A, et al. Clinical cross-reactivity among foods of the Rosaceae family. J Allergy Clin Immunol 2000; 106:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/43\">",
"      Cuesta-Herranz J, L&aacute;zaro M, Figueredo E, et al. Allergy to plant-derived fresh foods in a birch- and ragweed-free area. Clin Exp Allergy 2000; 30:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/44\">",
"      Rodriguez J, Crespo JF, Burks W, et al. Randomized, double-blind, crossover challenge study in 53 subjects reporting adverse reactions to melon (Cucumis melo). J Allergy Clin Immunol 2000; 106:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/45\">",
"      Liccardi G, Mistrello G, Noschese P, et al. Oral allergy syndrome (OAS) in pollinosis patients after eating pistachio nuts: two cases with two different patterns of onset. Allergy 1996; 51:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/46\">",
"      Barber D, de la Torre F, Feo F, et al. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy 2008; 63:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/47\">",
"      Skypala IJ, Calderon MA, Leeds AR, et al. Development and validation of a structured questionnaire for the diagnosis of oral allergy syndrome in subjects with seasonal allergic rhinitis during the UK birch pollen season. Clin Exp Allergy 2011; 41:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/48\">",
"      Ortolani C, Ispano M, Pastorello EA, et al. Comparison of results of skin prick tests (with fresh foods and commercial food extracts) and RAST in 100 patients with oral allergy syndrome. J Allergy Clin Immunol 1989; 83:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/49\">",
"      Dreborg S, Foucard T. Allergy to apple, carrot and potato in children with birch pollen allergy. Allergy 1983; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/50\">",
"      Vieths S, Hoffmann A, Holzhauser T, et al. Factors influencing the quality of food extracts for in vitro and in vivo diagnosis. Allergy 1998; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/51\">",
"      Asero R. Detection and clinical characterization of patients with oral allergy syndrome caused by stable allergens in Rosaceae and nuts. Ann Allergy Asthma Immunol 1999; 83:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/52\">",
"      Pauli G, Bessot JC, Dietemann-Molard A, et al. Celery sensitivity: clinical and immunological correlations with pollen allergy. Clin Allergy 1985; 15:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/53\">",
"      Bj&ouml;rkst&eacute;n F, Halmepuro L, Hannuksela M, Lahti A. Extraction and properties of apple allergens. Allergy 1980; 35:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/54\">",
"      Fern&aacute;ndez-Rivas M, Cuevas M. Peels of Rosaceae fruits have a higher allergenicity than pulps. Clin Exp Allergy 1999; 29:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/55\">",
"      Pastorello EA, Ortolani C, Farioli L, et al. Allergenic cross-reactivity among peach, apricot, plum, and cherry in patients with oral allergy syndrome: an in vivo and in vitro study. J Allergy Clin Immunol 1994; 94:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/56\">",
"      Ballmer-Weber BK, W&uuml;thrich B, Wangorsch A, et al. Carrot allergy: double-blinded, placebo-controlled food challenge and identification of allergens. J Allergy Clin Immunol 2001; 108:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/57\">",
"      Bolhaar ST, Tiemessen MM, Zuidmeer L, et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004; 34:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/58\">",
"      Ballmer-Weber BK, Vieths S, L&uuml;ttkopf D, et al. Celery allergy confirmed by double-blind, placebo-controlled food challenge: a clinical study in 32 subjects with a history of adverse reactions to celery root. J Allergy Clin Immunol 2000; 106:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/59\">",
"      L&uuml;ttkopf D, Ballmer-Weber BK, W&uuml;thrich B, Vieths S. Celery allergens in patients with positive double-blind placebo-controlled food challenge. J Allergy Clin Immunol 2000; 106:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/60\">",
"      Guin JD. Rosemary cheilitis: one to remember. Contact Dermatitis 2001; 45:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/61\">",
"      Oka K, Saito F, Yasuhara T, Sugimoto A. A study of cross-reactions between mango contact allergens and urushiol. Contact Dermatitis 2004; 51:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/62\">",
"      Kind F, Scherer K, Bircher AJ. Allergic contact stomatitis to cinnamon in chewing gum mistaken as facial angioedema. Allergy 2010; 65:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/63\">",
"      Minor JS, Epstein JB. Burning mouth syndrome and secondary oral burning. Otolaryngol Clin North Am 2011; 44:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/64\">",
"      Minguez-Sanz MP, Salort-Llorca C, Silvestre-Donat FJ. Etiology of burning mouth syndrome: a review and update. Med Oral Patol Oral Cir Bucal 2011; 16:e144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/52/11082/abstract/65\">",
"      Ebo DG, Hagendorens MM, Bridts CH, et al. Flow cytometric analysis of in vitro activated basophils, specific IgE and skin tests in the diagnosis of pollen-associated food allergy. Cytometry B Clin Cytom 2005; 64:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2402 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11082=[""].join("\n");
var outline_f10_52_11082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1250202\">",
"      - Oral allergy syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1250209\">",
"      - Pollen-food allergy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22906921\">",
"      Seasonal pollen allergies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22907059\">",
"      - Seasonal variation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8377411\">",
"      - Impact of cooking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1250309\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POLLEN-FOOD ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Foods associated with tree pollens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26942027\">",
"      - Birch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Foods associated with weed pollens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26942058\">",
"      - Ragweed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mugwort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6344447\">",
"      Foods associated with grass pollen (timothy, orchard)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Specific syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Celery-mugwort-spice syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mugwort-mustard syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Latex-fruit syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Food-food associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Peach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Melons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26941090\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26941097\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26941104\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26941111\">",
"      Objective testing for food allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26941118\">",
"      - Prick-by-prick skin testing with fresh foods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H292433\">",
"      - Commercial food extracts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26941132\">",
"      - IgE immunoassays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26941146\">",
"      Objective testing for pollen sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26941167\">",
"      Oral food challenges",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26941174\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26941181\">",
"      FUTURE DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2402\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2402|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/61/27615\" title=\"figure 1\">",
"      Peak pollen periods US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/1/16409\" title=\"figure 2\">",
"      Food-pollen relationships",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/50/801\" title=\"figure 3\">",
"      Latex food cross rxn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/46/9952\" title=\"figure 4\">",
"      OAS food food cross rxn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2402|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/47/13048\" title=\"table 1\">",
"      Risk of anaphylaxis with plant food allergens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/8/32904?source=related_link\">",
"      Central craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=related_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=related_link\">",
"      Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_52_11083="Evaluation emotional neglect";
var content_f10_52_11083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment for inadequate provision of affection, nurturance, or love",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ask:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How does the parent describe the child and his or her feelings toward the child?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How does the parent show the child affection?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there something about the child that is difficult for the parent to accept? (eg, unwanted pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How satisfied is the parent with his or her role as a parent?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What is the child's perception of the parent's approach to him or her?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Observe:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there warmth, affection, and caring in the parent child interactions?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Dubowitz, H, Giardino, A, Gustavson, E. Child neglect: guidance for pediatricians. Pediatr Rev 2000; 21:111.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11083=[""].join("\n");
var outline_f10_52_11083=null;
var title_f10_52_11084="Differential dx of hyperthermia";
var content_f10_52_11084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hyperthermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Environmental exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sepsis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Encephalitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brain abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetanus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Typhoid fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroid storm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pheochromocytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Catatonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignant hyperthermia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Hypothalamic stroke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Status epilepticus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebral hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroleptic malignant syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol, sedative-hypnotic withdrawal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylate, lithium toxicity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sympathomimetic toxicity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticholinergic toxicity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dystonic reactions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serotonin syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Lanken, PN, Manaker, S, Hanson, CW III (Eds), The Intensive Care Unit Manual, WB Saunders, Florida (in press).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11084=[""].join("\n");
var outline_f10_52_11084=null;
var title_f10_52_11085="Composite Asthma Severity Index";
var content_f10_52_11085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composite Asthma Severity Index (CASI) scorecard",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Final score*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Day symptoms and albuterol in the last 2 wk (15 percent of total score)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-9",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-13",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Night symptoms and albuterol in the last 2 wk (15 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5-14",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lung function measures (15 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        percent &gt;85",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        percent = 80-84",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        percent = 70-79",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        percent &lt;70",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Controller treatment (25 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No treatment",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Albuterol as needed",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-dose ICS",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-dose ICS + LABA or medium-dose ICS",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medium-dose ICS + LABA",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-dose ICS",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Exacerbations (30 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone burst",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone burst + hospitalization",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Maximum possible score",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICS: inhaled corticosteroids; LABA: long-acting b-agonists.",
"     <br/>",
"     * Scoring example: A participant taking albuterol as needed with 2 nights of symptoms, 5 days of symptoms, an FEV",
"     <sub>",
"      1",
"     </sub>",
"     value 87 percent of predicted, and 1 prednisone burst (without hospitalization) in the last 2 months would have a final CASI score of 5 (1 point for day symptoms, 1 point for night symptoms, 1 point for controller treatment, 0 points for lung function measures, and 2 points for exacerbations).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Singulair should be considered equivalent to low-dose ICS and scored as 2 points.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index - an outcome measure for use in children and adolescents. J Allergy Clin Immunol 2012; 129:694. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11085=[""].join("\n");
var outline_f10_52_11085=null;
var title_f10_52_11086="Rhabdomyosarc prognos stratify";
var content_f10_52_11086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rhabdomyosarcoma prognostic stratification and standard treatment assignment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Prognosis, (EFS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mets",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nodes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Excellent (&gt;85 percent)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Favorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        VA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Favorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        VA +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Orbit only",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        VA +XRT or VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        a",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or NX",
"       </td>",
"       <td>",
"        VA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Very good (70-85 percent)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Favorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Orbit only",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Favorable, excluding orbit",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        a",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or NX",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        I or II",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        a",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        VAC +(XRT, Gp II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        I or II",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        VAC +(XRT, Gp II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Good (50-70 percent)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        a",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or NX",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        a",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1, 2, 3",
"       </td>",
"       <td>",
"        I, II, III",
"       </td>",
"       <td>",
"        Favorable or unfavorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        ALV/UDS",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        I, II, III or IV",
"       </td>",
"       <td>",
"        Favorable or unfavorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        VAC +XRT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Poor (&lt;30 percent)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Favorable or unfavorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &ge;10",
"       </td>",
"       <td>",
"        EMB",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        See text",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Favorable or unfavorable",
"       </td>",
"       <td>",
"        a or b",
"       </td>",
"       <td>",
"        &lt;21",
"       </td>",
"       <td>",
"        ALV/UDS",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        N0 or N1 or NX",
"       </td>",
"       <td>",
"        See text",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Favorable: orbit/eyelid, head and neck (excluding parameningeal), genitourinary (not bladder or prostate), and biliary tract; Unfavorable: bladder, prostate, extremity, parameningeal, trunk, retroperitoneal, pelvis, other; a: tumor size 5 cm in diameter; b: tumor size &gt;5 cm in diameter. EMB: embryonal, botryoid, or spindle-cell rhabdomyosarcomas or ectomesenchymomas with embryonal RMS; N0: regional nodes clinically not involved; N2: regional nodes clinically involved; NX: node status unknown. VAC: vincristine, actinomycin D, cyclophosphamide; XRT: radiotherapy; Topo: topotecan; Gp: group; ALV/UDS: alveolar or undifferentiated sarcoma; EFS: event-free survival.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group Experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23:215. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11086=[""].join("\n");
var outline_f10_52_11086=null;
var title_f10_52_11087="Abnormal Ab IgG Patterns";
var content_f10_52_11087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Different patterns in the evolution of specific antibody and total immunoglobulin G (IgG) levels  Abnormal response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 603px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of serum tetanus toxoid antibodies (blue) and IgG levels (red) in four patients (C and D in this figure; A and B in accompanying figure) demonstrating various patterns in the evolution of specific antibody and IgG levels. Black arrowheads represent immunization with tetanus and diphtheria toxoid, poliovirus and Bordetella pertussis. The area above the dashed line indicates normal levels of tetanus toxoid antibodies (&ge;0.05 IU/mL). An abnormal pattern in which the patient failed to make specific antibodies after reimmunization and remained hypogammaglobulinemic (Figure C). An abnormal pattern in which the patient had substantial but unsustained response to reimmunization with a slow rise in total IgG to normal levels (Figure D).",
"    <div class=\"footnotes\">",
"     ABs: antibodies.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data published in Dalal I, Roifman C. Humoral immunodeficiency. In: Immunology and Allergy Clin North Am 2001; 21:129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_52_11087=[""].join("\n");
var outline_f10_52_11087=null;
